MAMMALIAN ICYP (IODOCYANOPINDOLOL) RECEPTOR AND ITS APPLICATIONS

Abstract: An isolated and substantially pure mammal polypeptide different from known adrenergic, serotonine and dopamine receptors, existing at least on mammalian muscle and eosinophils membranes, for instance in rat, guinea pig and humans. The invention also relates to plasmids containing the genes coding for said polypeptide, to host cells transformed by genes coding for the above mentioned polypeptide, to nucleotide probes capable of hybridizing with the genes coding for the above mentioned polypeptide, and to polyclonal and monoclonal antibodies directed against the above mentioned polypeptide. Said polypeptide is characterized in that it contains sites such that when said sites are exposed at the surface of a cell, they are able of binding iodocyanopindolol (ICYP) under blockage of alpha , beta 1, beta 2, beta 3-AR, serotonine 5-HT1A and serotonine 5-HT1B receptors, said binding being saturable, reversible, able to be displaced by a beta -adrenergic receptor agonist SM-11044 with stereoselectivity but not by isoproterenol, norepi-nephrine, epinephrine, serotonine, dopamine or BRL-37344, and not being blocked by propranolol, said polypeptide (1) having an apparent molecular weight of about 30-40 kDa when labeled with <125>I-iodocyanopindolol after photoaffinity labeling and separation by electrophoresis and an apparent molecular weight of about 60-80 kDa in Western blot, and (2) generating a fragment having the following formula DPX1FFQHRIHX2FSIFNX3 by acidic cleavage, wherein X1 represents S (SEQ ID NO.5) or X (SEQ ID NO.6), X2 represents V (SEQ ID NO.6) or W (SEQ ID NO.5) and X3 represents S (SEQ ID NO.5) or H (SEQ ID NO.6), said polypeptide being present at least on muscles and eosinophils membranes and being a non-adrenergic receptor.

Description: MAMMALIAN ICYP (IODOCYANOPINDOLOL) RECEPTOR AND ITS APPLICATIONS The present invention relates to an isolated and substantially pure mammal polypeptide different from known adrenergic, serotonine and dopamine receptors, existing at least on mammalian muscle and eosinophils membranes, for instance in rat, guinea pig and humans The invention also relates to plasmids containing the genes coding for said polypeptide, to host cells transformed by genes coding for the above mentioned polypeptide, to nucleotide probes capable of hybridizing with the genes coding for the above mentioned polypeptide, and to polyclonal and monoclonal antibodies directed against the above mentioned polypeptide and which can be used for the purpose of in vitro diagnosis, A wide vaπety of membrane receptors for hormones and neuro- transmitters are composed of a single polypeptide chain containing seven hydrophilic sequences and may be coupled to guanine-nucleotide-binding regulatory G proteins, which upon activation by agonists or antagonists, stimulate or inhibit vaπous effectors such as enzymes or ion channels Among the family of seven transmembrane domains receptors are those for adrenaline and other catecholamines, the adrenergic receptors and those for acetyl- choline and related muscaπnic Iigands, the muscaπnic chohnergic receptors Other similar proteins belonging to this growing family are those for serotonine, for dopamine, for tachykimns and for the pituitary glycoprotein hormones, to mention but a few The existence of atypical adrenergic receptors (AR), in adipocytes, in gastrointestinal tissues and in skeletal muscles has been well-established Atypical β- adrenergic receptors (β-ARs) are defined as β-AR that can not be classified as typical β- ARs (βl-AR and β2-AR) with low β-AR antagonist effect, showing a propranolol (a classical non-selective β-AR antagonιst)-resιstant feature For instance, McLaughlin, MacDonald and co-workers characterized β- AR in rat colon (McLaughlin, MacDonald, 1990; MacDonald and Lamont, 1993; McKean and MacDonald, 1995). Propranolol was a weak antagonist against isoproterenol and BRL-37344. The propranolol-resistant responses of isoproterenol were antagonized by cyanopindolol with a pA 2 value of 7.12 under blockade of βl- and β2-AR effects. They reported that responses to isoproterenol in rat colon were mediated largely through β3-AR with small contribution of βl-AR and β2-AR (McKean and MacDonald, 1995). This observation is supported by Ek et al., 1986, who found βl- and β2-AR in rat colon membranes by [ I25 I]-pindolol binding studies. Thus, rat colon has mainly β3-AR in addi- tion to βl- and β2-ARs. Like in guinea pig ileum, cyanopindolol acted as an antagonist at rat atypical β-AR, while it acted as a β l-, β2-AR antagonist having β3-AR agonist potency at human and mouse β3-AR (Blin et al., 1993). Most of the pharmacological features of atypical β-ARs can be explained by β3-AR-activity; however, lack of β3-AR transcripts in skeletal muscles, or hetero- geneous responses in vascular smooth muscles remained unexplained and show the complexity found in the field of receptors. The invention solves an unresolved question with regard to the existence of polypeptide having a receptor activity other than that of β3-adrenergic receptors; in fact, it provides access to a novel receptor class present at least in muscles and in eosino- phils, which displays transmembrane domains and may have signal transduction function. The Inventors have now found, unexpectedly, that in rat colon smooth muscle membranes, there is a non-adrenergic, non-serotonine and non-dopamine receptor mediating at least inhibition of depolarized colon tonus. The subject of the present invention is a substantially pure mammal polypeptide containing sites such that when said sites are exposed at the surface of a cell, they are able of binding iodocyanopindolol (ICYP) under blockade of α, βl, β2, β3-AR, serotonine 5-HT IA and serotonine 5-HT IB receptors, said binding being saturable, reversible, able to be displaced by a β-adrenergic receptor agonist SM- 11044 with stereo- selectivity but not by isoproterenol, norepinephrine, epinephrine, serotonine, dopamine or BRL-37344, and not being blocked by propanolol said polypeptide (1) having an apparent molecular weight of about 30-40 kDa when labeled with I-iodocyanopindolol after photoaffinity labeling and separation by electrophoresis and an apparent molecular weight of about 60-80 kDa in Western blot, and (2) generating a fragment having the following formula DPXιFFQHRιΗX 2 FSIFNX 3 by acidic cleavage, wherein, X! represents S (SEQ ID N°5) or X (SEQ ID N°6), X 2 represents V (SEQ ID N°6) or W (SEQ LD N°5) and X 3 represents S (SEQ ID N°5) or H (SEQ LD N°6), said polypeptide being present at least on muscles and eosinophils membranes and being a non-adrenergic receptor. Said new non-adrenergic receptor has the following affinities with different β3-AR agonists and antagonists: SM- 1 1044 stimulates guinea pig ileum relaxation of KCl-induced tonus more efficiently than rat white adipocyte lipolysis; SM- 1 1044 and BRL-35135A, a potent β3-AR agonist, display the additional property of inhibiting leukotriene B4 induced-guinea pig eosinophil chemotaxis, whereas isoproterenol and BRL-37344 had no such effect. This inhibition was unaffected by the non-selective β-AR antagonist, propranolol, but was antagonized by alprenolol, a βl-, β2-AR antagonist/β3-AR partial agonist. While rat colon indeed contains β3-AR (Bensaid M. et al., 1993) in addition to β2-AR with a small population of βl-AR (Arunlakshana O. et al., 1959), the instant invention clearly shows the existence of a novel functional binding site in rat colon. This site was characterized by ligand binding and photoaffinity labeling, revealing a novel binding protein, designated here Ro-SMBP (SM- 1 1044 binding protein or Rodent SM- binding protein). Said new non-adrenergic SM-binding protein has also been found in human muscles (smooth and striated) (Hu-SMBP); it contains at least the sequence SEQ LD NO: l. According to an advantageous embodiment of said protein it consists of SEQ LD NO.13. Said protein contains a hydrophobic C-terminal region of 356 residues, which may contain up to nine transmembrane regions. The invention also relates to an isolated and purified nucleic acid which encodes a mammalian receptor as hereabove defined and fragments thereof. In humans, said coding sequence includes at least SEQ ID NO:2. According to an advantageous embodiment of said coding sequence, it consists of SEQ ID NO: 14, which corresponds to SMBP cDNA. The said SEQ LD NO: 14 comprises in particular the following single restriction sites: BstU I, Hha I, HinP I, Ava I, Sma I, Xma I, BsaA I, Apa I, Ban II, Bspl20 I, Eco0109 I, Sea I, Xmn I, Dra I, Nsi I, PpulO I, Acc65 I, Ban I, Kpn I, Bspl407 I, Spe I, BspD I, Cla I, Hinf I, Tfi I, Avr II, Drd I, Esp3 I. Bpm I, PflM I, Bsm I, Alu I, BceF I, Bgl II, BstY I, ApaL I, Age I, BsrF I, Nsp I, Nsp7524 I, NspC I, as located in figures 19, 20 and 21. This sequence encodes a polypeptide of 576 amino acid residues which contains a hydrophilic N-terminal region of 220 residues and a hydrophobic C-terminal region of 356 residues. Said nucleic acid sequences in different mammals at least hybridizes with: - a 900 bp of SEQ LD NO:3, or - a 300 bp of SEQ D NO:4. Said fragments are useful for detection of the gene coding for the instant new non-adrenergic receptor. The subject of the present invention is also cDNA clones, characterized in that they comprise a sequence fragment coding for the instant non-adrenergic receptor. According to the invention, the clone designated 24.3 comprises 1,7 kb and includes SEQ LD NO: 2; it encodes the instant Hu-SMBP. The invention also relates to synthetic or non-synthetic nucleotide probes, characterized in that they hybridize with one of the nucleic acid as defined above or with their complementary sequences or their corresponding RNA, these probes being such that they do not hybridize with the genes or the messenger RNA coding for β- adrenergic receptors. Said probes are selected, for instance, from the group consisting of the hereabove mentioned 900 bp (SEQ ID NO:3) and 300 bp (SEQ ID NO: 4) fragments and from SEQ LD NO:7 to SEQ ID NO: 12, optionally labeled using a label such as a radioactive isotope, a suitable enzyme or a fluorochrome. SEQ ID NO:7 to SEQ LD NO: 12 may be used as primers for amplifying one of the instant nucleic acid sequence. The hybridization conditions are defined as follows, for the probes possessing more than 100 nucleotides: 600 mM NaCl; 60 mM Na-citrate; 8 mM Tris-HCl pH 7,5; 50 mM Na-phosphate; 1% Ficoll; 1% polyvinylpyrrolidone; 1% bovine serum albumine; 40% formamide; 0.2% SDS; 50 μg/ml salmon sperm DNA. The invention also relates to recombinant plasmid, cosmid or phage in particular for cloning and/or expression, containing a nucleic acid sequence of the inven- tion at one of its cloning sites (non essential for its replication). According to an advantageous embodiment of the said plasmid, it further comprises an origin of replication for replication in a host cell, at least one gene whose expression permits selection of said host cell transformed with said plasmid, and a regulatory sequence, including a promoter permitting expression of a polypeptide having a non- adrenergic activity as defined hereabove, in said host cell. According to an advantageous arrangement of this embodiment, the said plasmid is pcDNA3 into which is inserted, in a multisite linker, SEQ LD NO:2, wherein said plasmid is deposited with the Collection Nationale de Cultures de Microorganismes [National Collection of Microorganism Cultures] (CNCM held by the PASTEUR INSTITUTE, dated December 10, 1996, under No. 1-1795. The invention also relates to a host cell transformed by a recombinant plasmid as previously defined comprising the elements of regulation making possible the expression of the nucleotide sequence coding for the instant polypeptide in this host. Such a cell is capable of expressing a SMBP according to the instant invention. According to an advantageous embodiment, the host cell consists, in particular, in mammalian cell lines. The invention also relates to antibodies directed specifically against the instant polypeptide, these antibodies being such that they recognize neither known α or β adrenergic, nor serotonine, nor dopamine receptors. Advantageously, said new non-adrenergic receptor according to the invention constitute a tool for the selection of ligand participating in the activation or in the inhibition of these receptors. The invention also relates to a method for assaying a substance for agonist or antagonist activity towards a polypeptide according to the invention, which method comprises: - placing the substance in contact with tissue membrane proteins or a transformed host cell expressing a polypeptide according to the invention under conditions which permit binding between said polypeptide binding sites and an agonist or an antagonist thereto and - measuring an appropriate transduction signal. The invention also relates to a process for studying the binding affinity of a compound for a polypeptide according to the invention, which process comprises: - transforming a host cell by an expression vector comprising a nucleotide sequence coding for the instant receptor, - culturing said transformed host cell under conditions which permit the expression of said receptor encoded by said nucleotide sequence and the transfer of the expressed receptor polypeptide to the membrane of the said transformed host cell so that transmembrane sequences of said receptor polypeptide are embedded in the cell membranes of the transformed host cell; - placing said transformed host cell in contact with said compound and - measuring the quantity of said compound bond to said receptor polypeptide. The invention also relates to a process for studying the binding affinity of a compound for a polypeptide according to the invention, which process comprises: - extracting membrane proteins corresponding to the instant receptor polypeptide from appropriate tissues or cells such as muscles, - placing said membrane proteins in contact with said compound and - measuring the quantity of said compound bond to said receptor polypeptide. Functional roles of this polypeptide receptor would involve relaxation of depolarized-intestinal smooth muscle or inhibition of eosinophil chemotaxis. Specific agonist for this new receptor will display at least a therapeutic potentiality in gastrointestinal diseases based on depolarized-tonus, allergic asthma and hypereosinophilic syndrome based on eosinophil accumulation. Thus, the instant polypeptide receptor makes possible to develop drugs for at least gastrointestinal diseases based on depolarized-tonus, allergic asthma and hypereosinophilic syndrome. Besides the foregoing arrangements, the invention also comprises other arrangements which will become apparent from the description which follows, reference being made to the attached drawings wherein: . Figure 1 : Preparative SDS-PAGE followed by autoradiography of 50 mg solubilized rat colon membranes photoaffinity-labeled with 0.5nM [ 125 I]-ICYP- diazirine in the presence of 10 μM 5-HT, 10 μM phentolamine and 20 μM propranolol; . Figure 2: Analytical chemical cleavage of SMBP. The isolated-labeled protein of 34 kDa was incubated with distilled water (lane 1), 70% formic acid (lane 2), 10% cyanogen bromide in 70% formic acid (lane 3), 75% trifluoroacetic acid (lane 4) or 10% cyanogen bromide in 75% trifluoroacetic acid (lane 5) for 24 h at room temperature, separated by Tricine-SDS-PAGE followed by autoradiography. Arrows show 8, 10 and 12 kDa labeled fragments; Figure 3 Preparative cyanogen bromide-cleavage of SMBP The isolated-labeled proteins of 34 kDa were incubated with 10% cyanogen bromide in 70% formic acid for 24 h at room temperature An aliquot of the cleaved-products was resolved on tπcine-SDS-PAGE followed by autoradiography Arrows show 8. 10 and 12 kDa labeled fragments Figure 4 Analytical chemical cleavage of SMBP Fig 4a the partially purified labeled proteins were incubated with distilled water (lane 1), 70% formic acid (lane 2) or 1% cyanogen bromide in 70 % formic acid (lane 3) for 24 h at room temperature or Fig 4b the partially purified labeled proteins were incubated with distilled water (lane 1), 70% formic acid (lane 2) for 72 h at 37°C, separated by Tricine-SDS-PAGE and subjected to autoradiography Figure 5 Preparative acid-cleavage of SMBP The isolated-labeled protein of 34 kDa was incubated with 70% formic acid for 72 h at 37°C An aliquot of the cleaved-products was resolved on tπcine-SDS-PAGE followed by autoradiography Attows shows 8 kDa labeled fragment Figure 6 Reverse-phase HPLC purification of the photoaffimty-labeled formic acid-cleaved 8 kDa fragment The fragment isolated from tπcine-SDS-PAGE gels was further puπfied by reverse-phase HPLC Fragment was eluted from the C4 column with a linear gradient of 30-98% buffer B in 120 min ( — ) Radioactive profile for 8 kDa labeled fragment was shown (•) Based on the amount of recovered radioactivity, HPLC column recovery was 91 6% Figure 7 Enzyme immunoassay (ELISA) of antiserum (•), preimmunized-serum (O) or affinity-purified antibody (■, α8-antιbody) on plate coated with free peptide Rabbit polyclonal antibody was raised against the synthetic peptide corresponding to the N-terminal sequence of the 8 kDa fragment Figure 8 Immunoprecipitation of the solubilized photoaffinity-labeled SMBP Solubilized-rat colon membranes photoaffinity-labeled with 1 5 nM [ 125 I]-ICYP- diaziπne in the presence of 10 μM 5-HT, 10 μM phentolamine, 20 μM propranolol and 1. 1 mM ascorbic acid were immunoprecipitated by 1/200 diluted-preimmunized serum (lane 1) or 10 μg of α8-antibody (lane 2). . Figure 9: Western blotting of the rat colon membrane proteins. Lane 1 shows control (1/200 diluted-preimmunized serum was used). The 70 kDa band was detected by 2 μg/ml α8-antibody (lane 2). The detection was inhibited when antibody was preincubated with 10 μg/ml specific peptide (lane 3). . Figure 10: Relationship between the efficacy of β-AR agonists in the rat colon and white adipocytes, in the presence of 10 μM phentolamine and 1 μM propranolol. The linear regression line of the four agonists, except SM- 11044, is shown in figure (r=0.97, p < 0.05). The correlation coefficient, when calculated with SM- 11044, was not significant (r=0.87, p > 0.05). Data represent mean pD2 values ± SEM (from Table 1). . Figure 11 : Time-course of association (O, solid line) and dissociation (•, dashed line) of 1 nM [ 125 I]-ICYP specific binding to rat colon membranes, in the presence of 10 μM 5-HT, 10 μM phentolamine and 20 μM propranolol. Reversibility of binding was obtained by the addition of 100 μM SM-11044 at equilibrium (30 min). Data represent mean of two experiments performed in duplicate. . Figure 12: Total, non-specific and specific binding of [ 125 I]-ICYP to rat colon membranes, in the presence of 10 μM 5-HT, 10 μM phentolamine and 20 μM propranolol. Non-specific binding was determined in the presence of 100 μM SM- 11044. Data represent mean of two experiments performed in duplicate. The inset shows Scatchard's plot of the specific binding (r=-0.978, p < 0.001). The Kd was 11.0 ± 0.95 nM and the Bmax was 716.7 ± 21.12 fmol mg protein. . Figure 13: Displacement of 1 nM [ 125 I]-ICYP specific binding to rat colon membranes by (a) catecholamines, 5-HT and (b) stereo-isomers of SM- 11044, in the presence of 10 μM 5-HT, 10 μM phentolamine and 20 μM propranolol. Data represent mean of two to four experiments performed in duplicate. . Figure 14: SDS-PAGE followed by autoradiography of solubilized rat colon membranes photoaffinity-labeled with 1.5 nM [ I]-ICYP-diazirine in the presence of 10 μM 5-HT, 10 μM phentolamine and different competitors. Lane 1, control; lane 2, displacement by 20 μM propranolol; lane 3, displacement by 20 μM propranolol and 100 μM BRL-37344; lane 4, displacement by 20 μM propranolol and 100 μM SM-1 1044. . Figure 15: Two-dimensional SDS-PAGE followed by autoradiography of solubilized rat colon membranes photoaffinity-labeled with 1.5nM [ 125 I] ICYP-diazirine in the presence of 10 μM 5-HT, 10 μM phentolamine and 20μM propranolol. . Figure 16: Tryptic cleavage of the photoaffinity-labeled rat colon membranes. The partially purified labeled proteins were incubated without (lane 1) or with 50 μg trypsin (lane 2) for 24 h at 37°C, separated by Tricine- SDS-PAGE and subjected to autoradiography. Figure 17: Displacement of 1 nM [ I25 I]-ICYP specific binding to rat skeletal muscle membranes by SM- 1 1044 and (-)isoproterenol, in the presence of 10 μM 5-HT, 10 μM phentolamine and 20 μM propranolol. Data represent mean ± S.E.M of two experiments performed in duplicate. . Figure 18: Human multiple tissue northern blot hybridized with labeled 300 bp probe. Washes at 2 x SSC, 0.05% S.D.S, at room temperature and exposure on Hyperfilm MP with two intensifying screens at -80°C for three days. (A) Northern blot hybridization was performed on polyadenylated mRNA from 8 different smooth and striated human muscles. (B) similar analysis with a variety of non muscular tissues (heart, brain, placenta, lung, liver, kidney and pancreas). On the left: scale indicates RNA molecular weight marker in kilobases (Kb). . Figures 19, 20 and 21 illustrate the restriction map of SEQ LD NO: 14 (all sites: figure 19; unique sites only: figure 20 and figure 21). . Figure 22 illustrates a sequence comparison with known proteins (Arabidobsis protein, hMP70 protein, p76 protein, D87444 protein and Emp70 protein). . Figure 23 illustrates (A) a comparison of hydropathy profiles (Kyte & Doolittle) by GeneJockey Sequence Processor programm between SMBP and the homologous proteins D87444, Hu p76, hMP70 and Emp70 from yeast and Arabidobsis protein. (B) Comparison of the hydropathy profiles (Kyte & Doolittle method) of the C- terminal hydrophobic region between SMBP and the homologous proteins D87444, Hu p76 and Emp70 of yeast. . Figure 24 illustrates the sequences corresponding to the hydrophobic stretches (boxes). . Figure 25 illustrates immunoprecipitation of ( I)-iodinated cell membrane proteins by α8-antibody: lane 1 : COS cells transfected with a vector containing the angiotensin receptor AT2R; lane 2: COS cells transfected with a vector containing the SMBP nucleotide sequence. Example 1: Isolation and characterization of the instant receptor in rat colon smooth muscle membranes. 1) Materials and Methods SM-11044 ((L)-threo-3-(3,4-dihydroxyphenyl)-N-[3-(4-fluorophenyl) propyl] serine pyrrolidine amide hydrobromide) and (±)-cyanopindolol were synthesized at Sumitomo Pharmaceuticals (Osaka, Japan). (-)-3-[ 125 I] iodocyanopindolol ([ 125 I]-ICYP) and (±)-3 [ I25 I]-iodocyanopindolol-diazirine ([ 125 I]-ICYP-diazirine) were purchased from Amersham (Buckinghamshire, England). All other materials were reagent grade. Rat colon membrane preparation Frozen rat colons (SD strains, male and female) were purchased from Pel-Freeze Biologicals (Arkansas, USA). Membranes from colon smooth muscles were prepared as essentially described by Ek et al., 1986, with the slight following modifications. The colon segment was washed in ice-cold Tris-saline (10 mM Tris/HCl, 154 mM NaCl, (pH 7.4)), cut open longitudinally and the mucosa was removed by scrubbing with a glass slide on ice-cold plastic plate. The smooth muscle preparations were homogenized with a Polytron homogenizer for 1 min. The homogenate was filtered through a gauze and centrifuged (1,500 x g for 20 min at 4°C), the supernatant was collected and centrifuged (50,000 x g for 20 min at 4°C). The pellet comprising the membranes was resuspended in Tris-saline and was stored at -80°C until use. The protein concentration was determined by Bio-Rad protein assay kit (Bio-Rad USA). Binding assays in rat colon membranes Saturation binding studies were performed in a final volume of 200 μl of Tris-saline containing 50 μg membrane proteins and different concentrations (0.05-25 nM) of [ 125 I]-ICYP, in the presence of 10 μM serotonine (5-HT), 10 μM phentolamine, 20 μM (±) propranolol and 1.1 mM ascorbic acid (pH 7.4), to block possible 5-HT receptors, ARs and oxidation of catecholamines, respectively. The [ 125 I]-ICYP was used after removing methyl alcohol by compressed air to avoid the influence of the solvent. Incubations were carried out at 37°C for 30 min in a shaking water-bath incubator and terminated by addition of 4 ml of ice-cold Tris-saline followed by rapid filtration under vacuum on Whatman GF/B filter presoaked in Tris-saline containing 0.1% polyethyleneimine (pH 7.4). The filters were washed three times with 4 ml of ice-cold Tris-saline. transferred to plastic tubes and counted in a γ-counter. Photoaffinity labeling of the rat colon membranes Photoaffinity labeling was performed in a final volume of 10 ml of Tris- saline containing 50 mg membranes, 0.5 nM [ 125 I]-ICYP-diazirine, supplemented with 10 μM 5-HT, 10 μM phentolamine, 20 μM (±) propranolol and 1.1 mM ascorbic acid (pH 7.4) were incubated at 37°C for 60 min in the dark in a shaking water-bath incubator; the reaction was terminated by addition of 20 ml of ice-cold Tris-saline followed by a rapid centrifugation (50,000 x g for 10 min at 4°C). The membranes were resuspended in 2-3 ml of the same buffer and irradiated with a UV lamp for 10 min with cooling by circulating water (Guillaume et al., 1994). The labeled membranes were diluted with 20 ml of ice-cold Tris-saline, centrifuged (50000 x g for 30 min at 4°C). The labeled membranes were immediately denatured in SDS-reducing buffer (5% SDS, 1% 2β-mercaptoethanol, 10% glycerol, 0.002% bromophenol blue, 50 mM Tris/HCl, pH 6.8) for 1 h or more at room temperature before electrophoresis. Preparative SDS-PAGE and extraction of the photoaffinity-labelled proteins Preparative SDS-PAGE was performed with a large size (160 mm width x 200 mm height x 3 mm thickness) of 12% separating and 4% stacking polyacrylamide gels (40%) T, 2.6% C) under reducing conditions essentially according to the methods of Laemmli, 1970. After electrophoresis, the gels were packed in a plastic bag and auto- radiographed for 3 days at 4°C on X-OMAT™ AR film (Eastman Kodak Co., USA). The photoaffinity labeled proteins were extracted by passive extraction, as follows. The radio- active 34 kDa band was cut out and crushed to small pieces of less than 3x3x3 mm 3 by squeezing out using 10 ml disposable plastic syringe (Terumo, Japan). The gels were immersed in twice volume of 100 mM Tris/HCl (pH 8.0) containing 0.1% SDS (extraction buffer), and incubated for 16 h at 37°C with rotating. The extract was recovered using a SPLN-XII (0.45 μm pore size, Costar, USA) at 1,500 x g for 30 min. The remaining gel pieces were again immersed in twice volume of extraction buffer, incubated for 2 h at 37°C with rotating, and the extract was recovered as described above. The two extracts were combined and concentrated to at maximum 0.5 ml using Centriprep 10 and Centricon 10 (Amicon, USA) and kept at -20°C. Chemical cleavage of the extracts from preparative SDS-PAGE and purification by HPLC The 34 kDa photoaffinity-labeled protein extracted from the preparative SDS-PAGE were washed twice by distilled water using Centricon 10 and lyophilized by vacuum concentrator and treated with 200 μl of 70% formic acid or 10% CNBr/70% formic acid for 24 h at room temperature, or 70% formic acid for 72 h at 37°C in the dark. The cleaved products were diluted with 500 μl distilled water and lyophilized. This washing procedure was repeated three times. The cleaved products were dissolved in SDS-reducing buffer and neutralized by addition of aliquots of 30% NaOH until changing the coloration to blue, and were separated by tricine-SDS-PAGE. The gels were dried and autoradiographed. The labeled bands were cut out, passively extracted and blotted on PVDF membranes by centrifugation (ProSpin™, Applied Biosystems, USA). The membranes were washed 3 times with 1 ml of 20% methanol to remove SDS and salts. The fragments were extracted by 200 μl of 75% hexafluoro-isopropanol. Each elution was dried to 20 μl in vacuum concentrator, dissolved in 75μl DMSO and 75 μl of starting buffer (15% acetonitrile-15% isopropanol-0.5% TFA; buffer A) and loaded on a C4 reverse phase column (Aquapore Butyl BU-300, 2.1 mm ID, 10 mm length, Applied Biosystems). Separation was carried out by a 120 min gradient elution at 40°C with 50% acetonitrile-50% isopropanol containing 0.5% TFA (buffer B) at a flow rate of 0.35ml min using a Waters 625 LC System. The gradient started from 30% to 98% buffer B. The elution of fragments was monitored by the absorbance at 210 and 275nm, and the elution of radioiodinated products was monitored by γ-counting of the fractions. Tricine-SDS-PAGE Chemical cleaved fragments were separated on a Tricine gel system under reducing conditions (Schagger H. et al., 1987) using 18% polyacrylamide separating gel containing 10.7% glycerol. The gels aged for 16 h to allow for decomposition of reactive chemical intermediates after polymerization. Amino acid sequencing Amino acid sequence determination was performed by Edman degradation, 1967, with an Applied Biosystems 473 A protein sequencer. Samples were applied to precycled filters, coated with Polybrene (Biobrene, Applied Biosystems) to reduce peptide-wash-out and to improve initial yields. Antibody preparation Antibody was prepared as essentially described by Guillaume et al. (Eur. J. Biochem., 1994, 224, 761-770). Briefly, based on the determined amino acid sequences, peptides were synthesized adding a cysteine residue at C-terminal residue to facilitate coupling to the carrier protein (Keyhole limpet hemocyanin, KLH). The synthetic peptides were conjugated to KLH through their cysteine residues. A 0.4 mg of the peptide-conjugate, suspended in Freund's complete adjuvant, was intradermally injected into rabbit. Boosters were given 4 times at 2 weeks intervals by injection of a 0.2 mg of the peptide-conjugate suspended in Freund's incomplete adjuvant. Two weeks later the final immunization, antiserum was recovered from whole blood. Antibody was purified by affinity chromatography on a column containing the synthetic peptide coupled to activated thiol-Sepharose-4B (Pharmacia) through a cysteine at C-terminal residue, and the antibody titer level against the free peptide without conjugation to KLH was determined by ELISA. Immunoprecipitation Total amounts of 10 mg membranes were photoaffinity-labeled with 1.5 nM [ 125 I]-ICYP-diazirine in the presence of 10 μM, 5-HT, 10 μM phentolamine, 20 μM propranolol and 1.1 mM ascorbic acid in 10 ml of Tris-saline (pH 7.4). Membranes were solubilized at 1 mg membrane protein/ml of Tris-saline containing 2% n-octylgluco- side (n-octyl β-D-glucopyranoside, Sigma) for 2 h on ice with occasional mixing. The solubilized-proteins were separated from the insoluble material by centrifugation (200,000 x g, 30 min at 4°C). The proteins were treated with 8 M urea for 1 h at room temperature with occasional mixing and were washed 5 times with Tris-saline using Centricon 10. The solubilized-membrane proteins were dissolved in 1ml Tris-saline containing 0.1% Tween- 20 and were incubated with 10 μg antibody and 50 μl protein- A-agarose beads (Boehringer-Mannheim, Germany) for 16 h at 4°C with rotating. The precipitant was gently washed 5 times with ice-cold Tris-saline containing 0.1% Tween-20 and denatured in SDS-reducing buffer for more than 1 h at room temperature. The immunoprecipitated proteins were subjected to 12% SDS-PAGE and autoradiographed. Western blotting Photoaffinity-labeled membranes (40 μg protein) were separated by 12% SDS-PAGE. Electrotransfer of proteins onto nitrocellulose was carried out essentially according to Towbin et al, 1979, on a Trans-Blot SD apparatus (Bio-Rad) for 1 h at a current intensity of lmA/cm 2 . Nitrocellulose membranes were washed three times with Dulbecco's phosphate buffered saline (PBS) containing 0.2% Tween-20 and were saturated in PBS containing 5% skimmed milk powder and 0.2% Tween-20 for 1 h at room temperature. Antibody (2 μg/ml in PBS containing 1% skimmed milk powder and 0.2% Tween-20; buffer C) was allowed to react for 16 h at 4°C. After three times washing in buffer C, the nitrocellulose strips were incubated for 45 min at room temperature with peroxidase-conjugated affinity-purified Goat anti-rabbit IgG (Jackson Immuno-Research Laboratories, USA) at a 1/2500 dilution in buffer C, washed three times in buffer C. After washing in PBS containing 0.2% Tween- 20, reactive bands were visualized with an ECL kit (Amersham, England). In inhibition experiments, antibody was preincubated for 2 h at 37°C with free peptide at a concentration of 10 μg/ml in buffer C. 2) Results Extraction of the photoaffinity-labeled SMBP Membrane proteins of 2.0 g were collected from 600 rat colon smooth muscles. The ligand binding activity of SMBP was assessed by [ I]-ICYP under blockade of adrenergic and serotonine receptors. Scatchard plot analysis revealed a single class of binding sites with a dissociation constant (Kd) of 7.22 ± 0.007nM and a maximum number of binding sites (Bmax) of 1.13 ± 0.071 pmol/mg membrane protein (two independent experiments performed duplicate, expressed as means ± SD). The SMBP was too hydrophobic to separate by any column chromato- graphy such as reverse-phase HPLC with C4 column (Aquapore Butyl BU-300, Applied Biosystems), ion exchange chromatography (Aquapore Weak Anion AX-300, Applied Biosystems), chromatofocusing (PBE 94 and Polybuffer 74, Pharmacia), hydroxyapatite chromatography (BioGel HPHT, Bio-Rad). Preparative SDS-PAGE was performed to separate SMBP just after the photoaffinity labeling. Fifty mg of the labeled-membranes could be loaded on a set of polyacrylamide gels without serious diffusion of the 34 kDa labeled-SMBP (figure 1). The passive extraction of 34kDa bands yielded 79.3-86.2% of the total radioactive proteins in gels. Chemical cleavage, purification and sequencing Chemical cleavage has some advantage in contrast to proteolytic digestion; it avoids contamination by protease itself, and produces limited numbers of large fragments. Analytically, each 1 mg of the labeled 34 kDa protein was treated with 10% CNBr in 70% formic acid or in 75% TFA to compare the effect of acid. In formic acid condition, CNBr generated three labeled fragments of 8, 10 and 12 kDa, and formic acid alone generated a single 8 kDa labeled fragment. In the acid condition with TFA, most of the labeling was dissociated by acid itself, a single 10 kDa labeled fragment was observed by CNBr cleavage (figure 2). The extract of the labeled 34 kDa protein from 400 mg membranes (411794 cpm) was preparatively cleaved by CNBr/formic acid, and an aliquot of the cleaved-products was resolved on tricine-SDS-PAGE gels. Three labeled fragments of major 12 kDa and minor 8 and 10 kDa were observed on autoradiogram of coomasie blue stained gels (figure 3). Cleavage at methionine residues by CNBr/formic acid treatment for 24 h at room temperature of the photoaffinity-labeled 34 kDa protein yielded three labelled- fragments (8, 10 and 12 kDa, Fig. 4a, lane 3). Treatment by formic acid alone generated a single 8 kDa fragment (Fig. 4a, lane 2), and the density of the 8 kDa band increased upon prolonged incubation (for 72 h at 37°C, Fig. 4b, lane 2). The extract of the labeled 34 kDa protein from 400 mg membrane (381 198 cpm) was preparatively cleaved by formic acid, and an aliquot of the cleaved- products was resolved on tricine SDS-PAGE gels. A single labeled-fragment of 8kDa was observed on autoradiogram of coomasie blue stained-gels (figure 5). The radioactive 8 kDa fragment (total 21400 cpm) in preparative scale was extracted by passive extraction from tricine-SDS-PAGE gels without coomasie blue staining, and was blotted on PVDF membranes (19581 cpm). The fragment was extracted from PVDF membranes (10045 cpm) and further purified by reverse-phase HPLC. One radioactive peak was observed at 62%o buffer B (fraction n° 27 and 28; total 3239 cpm, figure 6). Total recovery yield of the initial radioactivity was 91.6%. The peak fractions were submitted to protein sequencer, and the resulting amino acid sequence was determined as follows: 1 5 10 15 (D) P X F F Q H R I H V F S I F N H (SEQ ID NO:6) Parenthesis; expected amino acid X; undetermined amino acid. Analytical CNBr-cleavage indicated that cleavage at methionine residue in the presence of TFA, which improve the cleave at CNBr-resistant bonds such as Met- Thr or Met-Ser (Fontana A. et al., 1986), generated a single 10 kDa fragment. In formic acid condition, CNBr generated three labeled fragments of 8, 10 and 12 kDa, and formic acid alone generated a single 8 kDa labeled fragment. These data suggest that 12 kDa fragment contains a CNBr-resistant methionine residue cleaved to 10 kDa by CNBr/TFA and that the 8 kDa fragment by formic acid alone is a product by cleavage at acid-sensitive bond such as Asp-Pro. Immunoprecipitation and Western blotting The peptide corresponding to the N-terminal sequence of the 8 kDa fragment (Acetyl-FFQHRLHVFSLFNHC) was coupled to KLH and the conjugate was used to raise antibody with high titer. The antibody response was observed at 2xl0 "5 dilution of antiserum and at 0.08 μg/ml of affinity purified antibody (α8-antibody) as assessed by ELISA against free peptide without conjugation to KLH (figure 7). The synthetic peptide corresponding to the 8 kDa-fragment was hydrophobic and could not be dissolved in a buffer without dimethyl sulfoxide. Initially, the labeled 34 kDa protein, extracted from preparative SDS-PAGE gels, was used after removing SDS, but no labeled protein was immunoprecipitated. After solubilization of the photoaffinity-labeled membranes by n-octylglucoside followed by denaturation with urea, the α8-antibody immunoprecipitated the labeled 34 kDa SMBP (figure 8). The α8-antibody recognized only a 70 kDa band by western blotting. The specificity of the antibody was demonstrated by the ability of the free peptide to inhibit the binding of the antibody to the 70 kDa protein (figure 9). In a separate experiment, photoaffinity-labeled SMBP was purified by two-dimensional electrophoresis in prepara- tive scale, and the 34 kDa labeled spot in gels was isolated, extracted and subjected to SDS-PAGE. Two labeled bands of 34 and 70 kDa derived from 34 kDa were observed, indicating that the 70 kDa protein could be dimer. Example 2: Pharmacological properties of the rat receptor according to example 1. Catecholamine-induced relaxant responses which are resistant to blockade of α-, βl- and β2-adrenoceptors (ARs) have been described in a number of gastro-intestinal smooth muscle preparations, such as guinea pig ileum (Bond R.A. et al., 1988), rat proximal colon (Croci T. et al., 1988), rat distal colon (McLaughlin D.P. et al., 1990), rat gastric fundus (McLaughlin D.P. et al., 1991) and rat jejunum (Van der Vliet A. et al, 1990). Manara et al., 1990, actually reported that the phenylethanolamino-tetralines- stimulated rat colon relaxation paralleled rat adipocyte lipolysis, suggesting that this response predominantly involved the β3-AR. 1) Materials and Methods Chemicals SM- 11044 ((L)-threo-3-(3,4-dihydroxyphenyl)-N-[3-(4-fluorophenyl) propyl] serine pyrrolidine amide hydrobromide), SM- 14786 ((D)-threo isomer of SM- 11044), SM-14011 ((DL)-threo-isomer of SM-1 1044), SM-14010 ((DL)-erythro-isomer of SM-11044), BRL-35135A ((R*R*)-(+)-4-[2'-[2-hydroxy 2-(3-chlorophenyl) ethyl amino] propyl] phenoxyacetic acid methyl ester), BRL-37344 (acid metabolite of BRL- 35135A) and (( l25 I)-cyanopindolol were synthesised at Sumitomo Pharmaceuticals (Osaka, Japan). CGP-12177A and CGP-20712A were gifts from Ciba-Geigy Corporation (Basal, Switzerland). ICI-198157 ((RS)-4-[2-[(2-hydroxy-3-phenoxypropyl) amino] ethoxy] phenoxyacetic acid methyl ester), ICI-201651 (acid metabolite of ICI- 198157) and ICI- 215001 ((S)-isomer of ICI-201651) and ICI-1 18551 were obtained from Zeneca Pharmaceuticals (Macclesfield, England). SR-58611A ((RS)-N-(7 carbethoxymethoxyl- l,2,3,4-tetrahydronaphth-2-yl)-2-hydroxy-2-(3 chlorophenyl) ethanamine hydro-chloride) was a gift from Sanofi-Midy (Milano, Italy). (+)-Carazolol was obtained from Boehringer Mannheim (Mannheim, Germany). (+)-Bupranolol was a gift from Schwarz Pharma (Monheim, Germany). (-)-3-[ 125 I] iodocyanopindolol ([ 125 I]-ICYP) and (+)-3 [ 125 I]- iodocyanopindolol-diazirine ([ I25 I]-ICYP-diazirine) were purchased from Amersham (Buckinghamshire, England). All other drugs were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Relaxation of rat colon Rat colon segment (2 cm) was suspended in organ bath containing 10 ml modified-Tyrode solution (Sugasawa T. et al., Eur. J. Pharmacol., 1992, 216, 207-215). The Tyrode solution contained 0.5 μM atropine, 0.5 μM desmethylimipramine, 30 μM hydrocortisone, 30 μM ascorbic acid, 10 μM phentolamine and 1 μM propranolol throughout study, in order to inhibit spontaneous contraction, neuronal and extra-neuronal uptake of norepinephrine, oxidation of catecholamines, possible α, βl- and β2-AR effects, respectively. The relaxant action of agonists was determined by measuring relaxation of KCl (100 mM)-induced tonus evoked by cumulative addition of the agonists as described previously (Sugasawa T. et al. cited above). In the case of testing the effect of cyanopindolol, it was added 5 - 10 min before the addition of agonist. Lipolysis in rat white adipocytes White adipocytes were isolated from epididymal fat pads of male Wistar rats (190 - 230 g) and lipolysis was determined according to the previous report (Sugasawa T. et al. cited above). The cells were preincubated for 5 min at 37°C in the presence of 30 μM ascorbic acid, 10 μM phentolamine and 1 μM propranolol. Agonists were then applied and incubated for 90 min. In the case of testing the effect of cyanopindolol, it was added 5 min before the addition of agonist. Schildplot Agonist concentration-ratios (CR) were determined from the EC50 values of the concentration-response curves of agonists with or without cyanopindolol, according to the method of Arunlakshana et al., 1959. Linear regression analysis was used to estimate the pA value and slope of the line, after confirming that the regression was linear and the slope was not significantly different from unity (Cochran-cox test, p > 0.05). The EC50 values were calculated using the computer program, InPlot Statistical analysis Results are expressed as mean ± SEM. Statistical significance between two data sets was examined by Student's t-test or Cochran-cox test, depending on the homogeneity of the variances. Duncan's multiple range test was used for multiple data sets. A probability level of p < 0.05 was considered to be significant. Membrane preparation Membranes from the colon smooth muscle and from skeletal muscle were prepared from male Wistar rats (300 - 360 g) as essentially mentioned in example 1. Binding assays in membranes Saturation binding studies were performed in a final volume of 200 μl of Tris-saline containing 50 μg membrane proteins and different concentrations (0.05-25 nM) of [ 125 I]-ICYP, supplemented with 10 μM serotonine (5-HT), 10 μM phentolamine, 20 μM propranolol and 1.1 mM ascorbic acid (pH 7.4), to block possible 5-HT receptors, ARs and oxidation of catecholamines, respectively. The [ 125 I]-ICYP was used after removing methyl alcohol by compressed air to avoid the influence of the solvent. Incubations were carried out at 37°C for 30 min in a shaking water-bath incubator and terminated by addition of 4 ml of ice-cold Tris-saline followed by rapid filtration under vacuum on Whatman GF B filter presoaked in Tris-saline containing 0.1 % polyethyleneimine (pH 7.4). The filters were washed three times with 4 ml of ice-cold Tris-saline, transferred to plastic tubes and counted in a γ-counter. Competition assays were performed against 1 nM [ I]-ICYP. Nonspecific binding was determined in the presence of 100 μM SM- 11044. The inhibition constant, Ki, of a ligand was calculated using the equation described by Cheng and Prusoff (Biochem. Pharmacol., 1973, 22, 3099-3108). Hill coefficient was calculated by linear regression using saturation experiment data. Pseudo-Hill coefficient and IC50 were determined by the computer program, InPlot™ (GraphPad Software, CA, USA). Photoaffinity labeling of the membranes Photoaffinity labeling was performed in a final volume of 1 ml of Tris- saline containing 0.5 mg membranes, 1.5 nM [ 125 I]-ICYP-diazirine, supplemented with 10 μM 5-HT, 10 μM phentolamine, 20 μM propranolol and 1.1 mM ascorbic acid (pH 7.4). Incubations were carried out in the presence or absence of competitor at 37°C for 45 min in the dark in a shaking water-bath incubator and terminated by addition of 10 ml of ice-cold Tris-saline followed by a rapid centrifugation (150,000 x g for 10 min at 4°C). The membranes were irradiated with a UV lamp for 5 min with cooling by circulating water. The labeled membranes were diluted with 10 ml of ice-cold Tris-saline, centrifuged (150,000 x g for 30 min at 4°C), and the pellet was resuspended in Tris-saline and kept at - 80°C. SDS-PAGE SDS-PAGE was performed under reducing conditions essentially as described by Laemmli, 1970, using 12% polyacrylamide gels (40% T, 2.6% C). The photoaffinity-labelled membranes were incubated in SDS-sample buffer (5% SDS, 1% 2β- mercaptoethanol, 10% glycerol, 0.002% bromophenol blue, 50 mM Tris/HCl, (pH 6.8)) for at least 1 h at room temperature. After electrophoresis, the gels were dried and autoradiographed on X-OMAT 7M AR film (Eastman Kodak Co., NY, USA), as specified in example 1, chapter «preparative SDS-PAGE». Two-dimensional PAGE of photoaffinity-labeled membranes Photoaffinity-labeled membranes in the presence of 10 μM 5-HT, lOμM phentolamine and 20 μM propranolol were solubilized in LEF-sample buffer (8 M urea, 0.3% SDS, 5.6% Triton X-100, 2.8% 2β-mercaptethanol, 1.1% Bio-Lyte 5/8 ampholyte and 0.6% Bio-Lyte 8/10 ampholyte (Bio-Rad)) and 30 μg of membrane proteins were submitted to LEF electrophoresis in a 5 - 10 pi range of 4% polyacrylamide tube gels containing 2.0%o Bio-Lyte 5/8 ampholyte, 1.0% Bio-Lyte 8/10 ampholyte, 8 M urea and 2% Triton X-100. The second dimension was conducted on SDS-PAGE of 9% poly- acrylamide gels. The gels were then dried and submitted to autoradiography as described above. Cleavage by endoglycosidase or N-glycopeptidase F Photoaffinity-labeled membranes in the presence of 10 μM 5-HT, lOμM phentolamine and 20 μM propranolol were treated with N glycopeptidase F (PNGase F, EC 3.2.2.18) or endoglycosidase (Endo Hf, EC 3.2.1.96), using kits according to the manufacturer's specifications (New England Bio-Labs, MA, USA). Briefly, the membranes were solubilized in 0.5% SDS and 1% 2β-mercaptethanol, and 40 μg of membrane proteins were incubated with 5000 units of PNGase F in the presence of 1% NP-40 or with 2000 units of Endo Hf for 3 h at 37°C. The digested samples were subjected to SDS- PAGE of 12% polyacrylamide gels. The gels were then dried and submitted to autoradiography as described above. Wheat germ agglutinine (WGA) - sepharose chromatography Photoaffinity-labeled membranes in the presence of 10 μM 5-HT, lOμM phentolamine and 20 μM propranolol were solubilized in 1% Triton X 100 in Tris-saline at 4°C for 16 h. The solubilized material was collected after centrifugation (200,000 x g for 1 h at 4°C) and diluted to 0.1% Triton X-100 by Tris-saline. One milliliter gel bed volume of WGA-sepharose 6MB (Sigma) was washed and equilibrated with 30 ml of 0.1% Triton X- 100 in Tris-saline (buffer A), and 1 ml of solubilized material containing 200 μg membrane proteins was loaded at room temperature. The unretained fraction was recycled three times. After washing with 10 ml of buffer A, the bound material was eluted with 5 ml of 300 mM N-acetyl-D-glucosamine (Merck) in buffer A. The fractions were subjected to SDS-PAGE of 12% polyacrylamide gels. The gels were then dried and submitted to autoradiography as described above. Tryptic cleavage The photoaffinity-labeled membranes were subjected to SDS-PAGE of 12% polyacrylamide gels. The gels were then dried and submitted to autoradiography as described above. The radioactive band at 34 kDa was excised, immersed in distilled water and minced to small pieces (2 mm width x 2 mm height). The isolated gel pieces corresponding to 800 μg membrane proteins was digested in 500 μl of 100 mM Tris/HCl (pH 8.0) containing 0.1% SDS and 50 μg trypsin (EC 3.4.21.4, Type IX from Porcine Pancreas, Sigma) for 24 h at 37°C according to the method of Kawasaki H. et al, 1990. After digestion, the supernatant was recovered and filtrated using a SPIN-X filter (0.45 mm pore size, Costar, MA, USA). The gel pieces were crushed through a nylon mesh (200 mesh) by centrifugation for 10 min at 14,000 x g. A 2-fold volume of 100 mM Tris/HCl containing 0.1% SDS was added to the crushed gels, and a second extraction was performed by incubation for 2 h at 37°C with rotating. After incubation, the supernatants were recovered by SPIN-X filter. The two extracts were combined, vacuum concentrated and submitted to Tricine-SDS-PAGE. Chemical The 34 kDa photoaffinity-labeled protein was isolated by SDS-PAGE and extracted with 100 mM Tris/HCl (pH 8.0) containing 0.1% SDS as described above. The extracts were combined and concentrated by Centricon 10 (Amicon, MA, USA) and washed twice by distilled water. The extracts were lyophilised by vacuum concentrator and treated with 200 μl of 70% formic acid or 1% CNBr/70% formic acid for 24 h at room temperature, or 70% formic acid for 72 h at 37°C in the dark. The cleaved products were diluted with 500 μl distilled water and lyophilised. This washing procedure was repeated three times. The cleaved products were separated by Tricine SDS-PAGE. Tricine-SDS-PAGE Tryptic and chemical cleaved fragments were separated on a Tricine gel system under reducing conditions (Schagger H. et al., 1987) using 18% polyacrylamide separating gel containing 10.7% glycerol. After electrophoresis, the gels were stained with 0.25% Coomassie brilliant blue R-250 (Sigma) in 40% methanol and 10% acetic acid, and destained in 10% acetic acid. The gels were then dried and submitted to autoradiography as described above. 2) Results Functional studies in rat colon and white adipocytes Under blockade of α-, βl- and β2-ARs (in the presence of 10 μM phentolamine and 1 μM propranolol), a number of β-AR agonists relaxed KCl-induced tonus in rat colon smooth muscle segment, giving a rank order of potency of BRL-37344 > SM-11044 » isoproterenol » norepinephrine = epinephrine (Table 1). TABLE 1 Agonist efficiency in rat colon relaxation and rat white adipocyte lipolysis in the presence of 10 μM phentolamine and 1 μM propranolol Statistical significance between IA values; * p < 0.05, ** p < 0.01 vs isoproterenol (Duncan's multiple range test). The I A value of SM- 11044 was significantly higher than that of isoproterenol (Duncan's multiple range test, p < 0.05), indicating different modes of action. In rat white adipocytes, the same agonists stimulated lipolysis with a rank order of potency of BRL-37344 » SM-11044 = isoproterenol > norepinephrine > epinephrine (Table 1). The linear regression line for isoproterenol, norepinephrine, epinephrine and BRL-37344 reveals a significant correlation (r=0.97, p < 0.05) between agonist induced rat colon relaxation and adipocyte lipolysis (Fig. 10), suggesting that both effects predominantly involve the same atypical β-, that is β3-AR stimulation. In contrast to the four Iigands, SM- 11044 stimulated colon relaxation more efficiently than adipocyte lipolysis (Fig. 10). Indeed, the correlation coefficient ceased to be significant when linear regression was analyzed with all agonists including SM-11044 (r= 0.87, p > 0.05). These data suggest that SM-11044 acts on β3-AR and additional functional site that mediates relaxation in rat colon. Antagonism of cyanopindolol for SM-11044 and for isoproterenol was compared in both preparations. Cyanopindolol itself, up to the concentration of 10 μM used here, had no effect on the degree of tonus induced by KCl in rat colon and did not stimulate lipolysis in rat white adipocytes. Cyanopindolol antagonised agonist-induced rat colon relaxation in a concentration-dependent manner, with pA 2 values for SM-11044 of 8.31 (slope = 0.78) and for isoproterenol of 7.65 (slope = 1.03) (Table 2). TABLE 2 pA 2 values for cyanopindolol in rat colon and rat white adipocytes in the presence of 10 μM phentolamine and 1 μM propranolol. Agonist Rat colon Rat white adipocytes pA 2 Slope n pA 2 Slope n (-)-isoproterenol 7.65±0.48 1.03±0.08 5 7.44±0.61 1.08±0.10 4 SM- 11044 8.31±0.88 0.78+0.1 1 5 7.32±1.51 0.96±0.21 4 Cyanopindolol also antagonized agonist-induced rat white adipocyte lipolysis in a concentration-dependent manner, with pA 2 values for SM 1 1044 of 7.32 (slope = 0.96) and for isoproterenol of 7.44 (slope = 1.08) (Table 2). The similar pA 2 values for isoproterenol in colon (7.65), SM-1 1044 in adipocytes (7.32) and isoproterenol in adipocytes (7.44) with the slopes close to unity, indicating the competitive antagonism of cyanopindolol for both agonists binding to β3-AR. All slopes of Schild plots were not significantly different from unity. However, only the slope for SM- 11044 in rat colon (0.78) seemed to be lower than unity with high pA2 value (8.31), suggesting that SM- 11044 and cyanopindolol compete not only binding to β3-AR but also to additional functional site on rat colon. Binding assays in rat colon membranes In order to identify the predicted functional site, being competed by SM- 1 1044 and cyanopindolol, binding studies in rat colon smooth muscle membranes were performed using [ 125 I]-ICYP for radioligand and SM-1 1044 for non-specific binding determination, under blockade of serotonine, α-, βl-, β2- and also β3-adrenergic receptors (in the presence of 10 μM 5-HT, 10 μM phentolamine and 20 μM propranolol). The time course of specific binding of [ 125 I]-ICYP (1 nM) to rat colon membranes was illustrated in Fig. 11. Specific binding achieved equilibrium levels at 30 min (82.7 ± 1.9%, n=2), and was reversed by addition of SM- 11044. The results of a saturation experiment with increasing amount of [ 125 I]-ICYP, carried out at equilibrium (30 min incubation), are illustrated in Fig. 12. Scatchard plot analysis revealed a single class of binding sites with a dissociation constant (Kd) of 1 1 0 ± 0 95 nM, and a maximum number of binding sites (Bmax) of 716 7 ± 21 12 fmol mg protein (r=-0 978, p < 0 001). Hill plot analysis of the saturation curve yielded a coefficient of 0 99 ± 0 03 (r=0 998, p < 0 0001), indicating the absence of cooperativity In competition binding studies, specific binding was not displaced by isoproterenol, norepinephrine, epinephrine, dopamine nor 5-HT, up to the concentration of 1 mM (Fig. 13a, Table 1) The competition binding by isomers of SM- 1 1044 was stereo- selective, SM-14011 (the racemic threo isomer, Ki 2.0 μM) being 15 times more effective than SM-14010 (the racemic erythro-isomer, Ki 29 3 μM) (Fig. 13b, Table 3) The βl-AR antagonist, CGP20712A and the β3-AR agonist, BRL-37344 did not displace the specific binding up to the concentration of 100 μM; the β2-AR antagonist, ICI-1 18551 was effective with a relatively high Ki (28 5 μM) (Table 3) Cyanopindolol was the most effective competitor with a Ki of 0 1 1 μM, and pindolol had no effect up to the concentration of 100 μM Carazolol, a ligand structurally related to cyanopindolol, was less effective, in spite of being more lipophilic (Table 3). Interestingly, BRL-35135A (methyl ester of BRL- 37344) and ICI 198157 (methyl ester of ICI-201651; ICI-215001, a (S)-enantiomer of ICI-201651) displaced the specific binding, whereas the corresponding acid metabolites were inactive (Table 3) The specific binding was significantly reduced by GTP (29 8 ± 2.7% inhibition at 300 μM (p < 0 01) and 98 2 ± 1 3% at 1 mM (p < 0 001), n=2, respec- tively) TABLE 3 Photoaffinity labeling study Photoaffinity labeling was performed to visualize the specific binding site in rat colon membranes using [ 125 I]-ICYP-diazirine. In the presence of 10 μM 5-HT and 10 μM phentolamine, but in the absence of propranolol, a single dense band of 34 kDa was visualized in addition to two broad bands with apparent molecular masses of 50 and 70 kDa. (Fig. 14, lane 1). In contrast, in the presence of 20 μM propranolol, 10 μM 5-HT and 10 μM phentolamine, that is, in the same conditions of the competition binding assay with [ 125 I] ICYP, only the 34 kDa band remained visible (Fig. 14, lane 2). These results suggest that the two broad bands are β-ARs. Moreover, the 34 kDa band was not displaced by 100 μM BRL-37344, but was displaced by 100 μM SM-1 1044 (Fig. 14, lanes 3 and 4, respectively). These data support the results of the competition binding assay, suggesting the existence of a single specific binding site for [ I25 I]-ICYP and SM-1 1044. Two-dimensional PAGE of the photoaffinity-labeled membranes confirmed the labeling of a single 34 kDa polypeptide chain corresponding to a pi of 6.0 (Fig. 15). The molecular size of the photoaffinity-labeled 34 kDa protein was not modified by the enzymatic treatments with endoglycosidase or N glycopeptidase F, whereas both enzymes reduced the molecular size of ovalbumin from 43 kDa to 40 kDa. Solubilized photoaffinity-labeled 34 kDa protein (373,298 cpm), were applied to a WGA-sepharose column. The unretained fraction contained 35.7% of the radioactivity, and washed out fractions contained 53.3%) of the radioactivity. The specific sugar, 300 mM N-acetyl-D- glucosamine, eluted only 2.3% of the radiolabeled material. The eluted fraction was subjected to SDS-PAGE after concentration, but the photoaffinity-labeled 34 kDa band was not detected. A single 7 kDa labeled-peptide was generated upon digestion of the photoaffinity-labeled 34 kDa protein with trypsin (Fig. 16). Recovery yields in final extracts from the gel pieces were 62.7% for the labeled 34 kDa protein and 90.4% for the in-situ generated tryptic peptides. Binding studies in rat skeletal muscle membrane preparation [ 125 I]-ICYP specific binding to skeletal muscle membranes was not displaced by isoproterenol up to concentrations of 10 M. In contrast, SM- 1 1044 displaced the binding in a concentration-dependent manner (Figure 17). Pharmacological definition of the instant receptor - SM- 1 1044, a β-AR agonist, showed atypical agonist effects such as relaxant responses in guinea pig ileum and rat colon intestines, and inhibition of guinea pig eosinophil chemotaxis. Cyanopindolol competitively antagonized the responses to isoproterenol and SM-11044 at β3-AR with similar pA2 values (7.32 - 7.65) in rat colon intestinal segments and rat white adipocytes. The values were also similar to those reported at β3- AR on rat white adipocytes (Kirkham D. et al., 1992), rat colon, rat gastric fundus (McLaughlin and MacDonald, 1989, 1990), and guinea pig ileum (Blue D.R. et al., 1989). In contrast, cyanopindolol antagonized the additional atypical effect of the SM-11044- induced colon relaxation with higher pA2 value (8.31) along with low slope of Schild plots (0.78). The results demonstrated the existence of at least two different affinity sites including β3-AR in rat colon. Thus, cyanopindolol and SM-1 1044 competed not only at β3-AR but also at another atypical binding site. SM-11044 stimulated relaxant responses of the KCl-induced depolarized colon tonus through both sites. Initial comparison with atypical effects between guinea pig ileum and rat white adipocytes could not exclude species-related difference. However, the difference of atypical effects between rat white adipocytes and rat colon intestines are now evident, that is not species-related phenomenon. - Detection of the binding site: radioligand binding assay was performed using rat colon smooth muscle membranes based on the results in functional studies that SM-11044 and cyanopindolol competed the sites. In general, if same origin of Iigands are used for both radioligand and «cold» ligand, physically- or chemically-related non-specific binding can not be excluded. Furthermore, pA 2 value of cyanopindolol was 8.31 and pD 2 value of SM-11044 was 7.29 in rat colon, suggesting 10-fold higher affinity of cyano- pindolol than that of SM-1 1044 at the two atypical components (β3-AR and another site). Therefore, [ 125 I]-ICYP and SM-1 1044 were used as radioligand and «cold» ligand, respectively. [ I25 I]-ICYP can bind to βl-, β2-, β3-ARs, serotonine 5-HT 1A and 5- HT I B receptors (Tate K.M. et al., 1991; Hoyer D. et al., 1994). In contrast, specific binding was obtained under blockade of these known receptors. Competition binding studies revealed that the binding site was indeed different from these receptors. Natural AR Iigands (epinephrine and norepinephrine) and classical β-AR ligand (isoproterenol) showed no affinity, suggesting that the binding site is different from ARs. Several synthetic β-AR Iigands including β3-AR agonists (BRL-35135A, SR-58611A and ICI-198157) showed affinity. Atypical effects that could not be explained by β3-AR can be resolved by the existence of this binding site. Indeed, similar binding sites under blockade of β-ARs and serotonine receptors were observed in rat skeletal muscle membranes. - Biochemical characterization by photoaffinity-labeling study The binding site in rat colon smooth muscle membranes was visualized by [ 125 I]-ICYP-diazirine, a photoaffinity ligand corresponding to [ 125 I]-ICYP. The apparent molecular size of the site was 34 kDa with an isoelectric point (pi) of 6.0. Deduced molecular sizes of rat β-ARs, serotonine 5-HT IA and 5-HTJ B receptors are 43.2 ~ 50.5 kDa (βl-AR, 50.5 kDa; β2-AR, 46.9 kDa; β3-AR, 43.2 kDa; 5-HTι A , 46.4 kDa, 5-HTm, 43.2 kDa) (Machida et al., 1990; Gocayne et al., 1987; Muzzin P. et al., 1991; Granneman JG. et al., 1991; Albert A. et al., 1990; Fujiwara et al., 1990, Voigt et al., 1991). In cells or tissues, these receptors are normally glycosylated, then the sizes are usually bigger than the deduced sizes. In contrast, the size of 34 kDa seemed to be smaller than these cloned rat receptors. One explanation may be devoid of N-linked glycosylation. The isoelectric point indicates that the binding site is an acidic protein like β-ARs (Fraser CM., 1984). Chemical cleavage at mostly methionine residues resulted in 10 and 12 kDa, and acid cleavage at mainly asparagine-proline bonds resulted in 8 kDa, indicating this protein contains methionine residues and may include asparagine-proline bonds. Example 3: Isolation and characterization of the instant receptor in human skeletal muscle. - Preparation of probes SEQ ID NO 6 has been compared to GenBank and EMBL data base by tblastn program (Altschul S F et al , 1990), in dbest data base, a human expressed sequence tag (EST) with almost 100% homology with SEQ ID NO 6 was found, it corresponds to SEQ LD NO 5, found in H sapiens as a partial cDNA sequence, clone 72F05, translated in frame 1 in the form of SEQ ID NO 5 However, it was not known whether or not said SEQ LD NO 5 could have any biological function In view to obtain the instant non-adrenergic receptor including SEQ LD NO 1 or NO 13, plasmid DNA containing human clone designated 72F05 (EMBL accession n° z28655) (Auffray C et al , 1995), including the corresponding coding sequence of SEQ LD NO 5 was obtained from Genethon, France and was used for prepaπng probes useful for hybπdization assays 900 bp probe (SEQ LT) NO:3) Cutting said plasmid DNA with restπction endonuclease EcoRI (New England Biolabs ref 101 S) released a 0 9 kb insert corresponding to clone 72F05 This fragment was isolated using QiaEX II agarose gel extraction kit (Qiagen ref 20021) 300 bp probe (SEQ LD NO:4): 1) Design of sens and anti-sens pπmers for PCR sens pπmer S4 (SEQ TD NO 7) anti-sens pπmer S6 (SEQ LD NO 8) 2) PCR on clone 72F05 Amplification was performed on 1 ng of plasmid DNA corresponding to clone 72F05, in the presence of the following reagents each primer at 0 25 μM, 10% DMSO, 2 5 U of Taq polymerase (Promega), 0 25 mM of dNTP (dATP, dCTP, dGTP, dTTP), reaction buffer was supplied by Promega and supplemented with 1 5 mM MgCb PCR was performed on Perkin Elmer « Gene Amp PCR System 9600 » using the following conditions: 4 min at 95°C 30 sec at 95°C f 30 sec at 48°C \ 30 cycles 30 sec at 72°C r 4 min at 72°C Under these conditions, a 0.3 kb fragment corresponding to the published sequence of clone 72F05 was amplified. The fragment was isolated using QiaEXII agarose gel extraction kit (Qiagen ref. 20021). - Radiolabeling of probes: By random priming (Feinberg et al., 1983) 50 μCi of dATP α32P (ICN ref. 39010 X) were incorporated to radiolabel DNA fragments. - Northern blot: A human multiple tissue northern blot was purchased from Clontech (ref. 7765-1). This blot ready to hybridize contained in each lane approximatively 2 μg of polyadenylated mRNA from 8 different human muscles (smooth and striated): lanes 1-8 in order: human skeletal muscle, uterus (no endometrium), colon (no mucosa), small intestine, bladder, heart, stomach, and prostate (see figure 18A). The membrane was hybridized following the suppliers instructions with labeled 300 bp probe (SEQ LD NO:4) (10 6 cpm/ml) during 24 hours. Washes were carried out under different stringency: 1) low stringency: 2x SSC; 0.05% S.D.S. at room temperature. Exposition of Amersham Hyperfilm MP at -80°C for 3 days using two intensifying screens showed three different fragments: 2 major bands are present in all samples; one at 3.4 kb and one at 3.8 kb. One fainter band, around 7 kb is found in all samples. 2) high stringency: 0.1 x SSC; 0.05% S.D.S. at 50°C; same exposition showed the same fragments in all samples. The results are illustrated in figure 18 (same results with low or high stringency). The visualized mRNAs correspond to SMBP transcripts. One explanation for the presence of 3 different transcripts could possibly be the utilization of alternative polyadenylation sites on SMBP gene (Intervening Sequences in Evolution and Development; E.M. Stone and R.J. Schwartz Oxford University Press 1990). A similar analysis done with a variety of non muscular tissues (heart, brain, placenta, lung, liver, kidney and pancreas) confirmed these observations (figure 18B). - Cloning of human cDNA: A human skeletal muscle cDNA library was purchased from Clontech (ref. HL 300s; lot 32288). 500,000 clones were transferred to nylon membranes (Hybond N+; Amersham) and screened by hybridizing either with probe 300 bp (SEQ LD NO:4) or with probe 900 bp (SEQ LD NO:3). Hybridization conditions were: 600 mM NaCl; 60 mM Na-citrate; 8 mM Tris-HCl pH 7,5; 50 mM Na- phosphate; 1% Ficoll; 1% polyvinylpyrrolidone; 1% bovine serum albumine; 40% forma- mide; 0.2% SDS; 50 μg/ml salmon sperm DNA. Radiolabeled probe was added at 10 6 cpm/ml and incubated overnight at 42°C. Final washes were at 50°C; 0.1 x SSC; 0.05% SDS for 1 hour. 11 positive clones were identified by repeated rounds of screening. Insert sizes were analyzed by simultaneous cutting with the following restriction endonucleases: Xba I/Hind III and Xba I/Bam HI (New England Biolabs). These enzymes released cDNA inserts from the vector pcDNA I (Invitrogen). All clones were sequenced with T7 and SP6 primers from both ends and found to be overlapping. The longest cDNA insert (clones n°24 and n°15) was about 1 7 kb and the smallest was about 0 65 kb (clone n°2) Clone 24 was sequenced on both strands using T7 and SP6 primers and the following specific primers Plus strand pπmers S4 SEQ LD NO 7 56 SEQ LD NO 8 58 SEQ LD NO 9 Minus strand primers S5 SEQ LD NO 10 57 SEQ LD NO 1 1 59 SEQ LD NO 12 DNA sequencing data showed a continuous open reading frame (SEQ ID NO 2 or NO 14), translation into protein sequence (SEQ LD NO 1 or NO 13) showed several hydrophobic stretches (figure 23), suggesting that these regions are putative membrane spanning parts of the protein The sequences corresponding to said hydrophobic stretches are highlighted (boxes) in figure 24 SMBP appears to share structural homologies with members of a group of proteins described as « similar » to Saccharomyces cerevtsiae EMP 70 protein precur- sor Figure 22 shows that - human myeloblastic cell line D87444 (Nagase T et al , DNA Res , 1996, 3, 321-329) is 30% homologous to SMBP, - p76 protein (Schimmoller F et al , accession number U81006) is 27% homologous to SMBP, - the yeast endomembrane protein (Emp70) which is a precursor of a 24 kDa protein (Emp24) involved in intracellular vesicular trafficking (Schimmoller F et al., EMBO J , 1995, 14, 7, 1329-1339) is 23% homologous to SMBP, - hMP70 (Chluba-de Tapia J. et al., Gene, 1997, 197, 195-204) is 28,5% homologous to SMBP whereas - a protein from Arabidopsis thaliana (accession number U95973) is 51,2% homologous to SMDP. The hydropathy plot of SMBP bears remarkable similarities to those of p76 protein, the myeloblast derived protein, hMP70 protein, Arabidobsis protein and Emp70 protein (see figure 23). The affinity-labeled peptide sequence is located at the switch region between the hydrophobic N-terminal part of SMBP and the C-terminal hydrophobic stretch which contains the transmembrane regions. The absence of N-glycosylation sites, the lack of homology with plasma membrane receptors and the similarity to intracellular proteins suggest that SMBP could indeed also be an intracellular membrane protein. SMBP appears to be expressed in many different tissues, and could therefore play a major role in normal cellular function. Since SMBP appears to be quite homologous to at least Emp70, involved in intracellular trafficking, i.e. ER via Golgi apparatus; this could also be a role for SMBP. Example 4: Construction of a plasmid for the expression of Hu-SMBP. For in vitro expression in mammalian cells, 1.7 kb cDNA insert of clone 24 was subcloned into the mammalian expression vector pcDNA3 (Invitrogen). Simulta- neous cutting by restriction endonuclease Xba I and Hind III (New England Biolabs) released the 1.7 kb insert from the pcDNA I vector (see example 3). The fragment was then blunt ended using Klenow fragment (Maniatis et al., Molecular Cloning, 2nd edition, 1, 5.40) and purified on 0.7% agarose gel using QiaEX II agarose gel extraction kit (Qiagen ref. 20021). Vector pcDNA3 was cut in the multisite linker by Eco RV (New England Biolabs) and dephosphorylated using calf intestinal alkaline phosphatase (New England Biolabs). After heat inactivation of phosphatase, the vector and the insert were ligated using T4 DNA ligase (New England Biolabs). Subclone 3 was selected (designated as clone n°24.3). This plasmid contains at least SEQ LD NO:2. Said recombinant plasmid may be transfected into mammalian cell lines for in vitro expression. Example 5: Expression of SMBP in COS cells. COS cells were transiently transfected with a vector containing the SMBP nucleotide sequence. The antibodies raised against a synthetic peptide (α8 antibodies) corresponding to the affinity-labeled fragment of rat SMBP were used for immunoprecipitation of proteins extracted from COS cells transfected with the human 17-r SMBP cDNA and labeled by I iodine using the chloramine T procedure. The precipitate was then redissolved and submitted to SDS-PAGE. A single protein with an apparent molecular weight of 45 kDa was identified after autoradiography (figure 25). Bibliography: * Albert A. et al., J. Biol. Chem., 1990, 265, 5825-5832. * Altschul SF et al., J. Mol. Biol. 1990, 215, 403-410. * Arunlakshana O. et al., Br. J. Pharmacol. Chemother., 1959, 14, 48-58. * Auffray C. et al., C. R. Acad. Sci. Ill, Sci. Vie, 1995, 318(2), 263-272. * Bensaid M. et al., FEBS Letters, 1993, 318, 223-226. * Blin N. et al., Mol. Pharmacol., 1993, 44, 1094-1104. * Blue D.R. et al., Br. J. Pharmacol., 1989, 96, 246. * Bond R.A. et al., Br. J. Pharmacol., 1988, 95, 723-734. * Croci T. et al, Pharmacol. Res. Commun., 1988, 20, 147-151. * Edman P. et al., Eur. J. Biochem., 1967, 1, 80-91. * Ek B.A. et al., Gastroenterology, 1986, 90, 408-413. * Feinberg et al., Anal. Biochem., 1983, 132, 6-13 * Fontana A. et al., Fragmentation of polypeptides by chemical methods, Practical Protein Chemistry, A handbook (edited by A. Darbre), John Willy & Sons Ltd., New York, USA. 67-120 (1986)). * Fraser CM., Receptor Biochemistry and Methodology, 1984, vol. 4 (J.C. Venter, CM. Fraser and J. Lindstrom, Eds), Alan R. Liss, Inc., New York , USA, 69-84. * Fujiwara et al., Life Science, 1990, 47, PL 127-132. * Guillaume JL. et al., Eur. J. Biochem, 1994, 224, 761-770. * Gocayne et al., P.N.A.S., 1987, 84, 8296-8300. * Granneman JG. et al., Mol. Pharmacol., 1991, 40, 895-899. * Hoyer D. et al., Pharmacol. Rev., 1994, 46, 157-203. * Kawasaki H. et al., Anal. Biochem., 1990, 191, 332-336. * Kirkham D. et al., Br. J. Pharmacol., 1992, 105, 23 IP. * Laemmli U.K., Nature, 1970, 227, 680-685. * MacDonald A. et al., Br. J. Pharmacol., 1993, 110, 1551-1555. * Machida et al., J. Biol. Chem., 1990, 265, 12960-12965. * Manara L. et al., Trends Pharmacol. Sci., 1990, 11, 229-230. * McKean J. et al., J. Pharm. Pharmacol., 1995, 47, 388-391. * McLaughlin D.P. et al., Br. J. Pharmacol, 1990, 101, 569-574. * McLaughlin D.P. et al., Br. J. Pharmacol., 1991, 103, 1351-1356. * Muzzin P. et al., J. Biol. Chem., 1991, 266, 24053-24058. * Schagger H. et al., Anal. Biochem., 1987, 166, 368-379. * Sugasawa T. et al., Eur. J. Pharmacol., 1992, 216, 207-215. * Tate K.M. et al., Eur. J. Biochem., 1991, 196, 357-361. * Towbin H. et al., Proc. Natl. Acad. Sci. USA, 1979, 76, 4350-4354. * Van der Vliet A. et al., J. Pharmacol. Exp. Ther., 1990, 255, 218-226. * Voigt et al. , EMBO J. , 1991 , 10, 4017-4023. As emerges from the foregoing, the invention is no way limited to those of its embodiments and modes if implementation and application which have just been described more explicitly; it encompasses, on the contrary, all variants which may occur to the specialist in the field, without departure from the scope or range of the present inven- tion. SEQUENCE LISTING (1) GENERAL INFORMATION: . (i) APPLICANT: (A) NAME: VETIGEN (B) STREET: 21 rue Sebastien Mercier (C) CITY: PARIS (E) COUNTRY: FRANCE (F) POSTAL CODE (ZIP) : 75015 (A) NAME: LENZEN Gerlinde (B) STREET: 55 rue des Cevennes (C) CITY: PARIS (E) COUNTRY: FRANCE (F) POSTAL CODE (ZIP) : 75015 (A) NAME: STROSBERG Arthur Donny (B) STREET: 66 rue de Javel (C) CITY: PARIS (E) COUNTRY: FRANCE (F) POSTAL CODE (ZIP) : 75015 (A) NAME: SUGASAWA Toshinari (B) STREET: 9-12-507 Miyano-cho, Ta atsuki-shi (C) CITY: OSAKA ( E) COUNTRY : JAPON (F) POSTAL CODE (ZIP) : 569 (A) NAME: MOROOKA Shigeako (B) STREET: 4-78 nishi-3 , Sei adai, Kawanishi-shi (C) CITY: HYOGO (E) COUNTRY: JAPON (F) POSTAL CODE (ZIP) : 666-01 (ii) TITLE OF INVENTION: NON-ADRENERGIC RECEPTOR AND ITS APPLICATIONS, (iii) NUMBER OF SEQUENCES: 14 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.30 (EPO) (2) INFORMATION FOR SEQ ID NO : 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 439 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: Met Tyr He Asp Asp Leu Pro He Trp Gly He Val Gly Glu Ala Asp 1 5 10 15 Glu Asn Gly Glu Asp Tyr Tyr Leu Trp Thr Tyr Lys Lys Leu Glu He 20 25 30 Gly Phe Asn Gly Asn Arg He Val Asp Val Asn Leu Thr Ser Glu Gly 35 40 45 Lys Val Lys Leu Val Pro Asn Thr Lys He Gin Met Ser Tyr Ser Val 50 55 60 Lys Trp Lys Lys Ser Asp Val Lys Phe Glu Asp Arg Phe Asp Lys Tyr 65 70 75 80 Leu Asp Pro Ser Phe Phe Gin His Arg He His Trp Phe Ser He Phe 85 90 95 Asn Ser Phe Met Met Val He Phe Leu Val Gly Leu Val Ser Met He 100 105 110 Leu Met Arg Thr Leu Arg Lys Asp Tyr Ala Arg Tyr Ser Lys Glu Glu 115 120 125 Glu Met Asp Asp Met Asp Arg Asp Leu Gly Asp Glu Tyr Gly Trp Lys 130 135 140 Gin Val His Gly Asp Val Phe Arg Pro Ser Ser His Pro Leu He Phe 145 150 155 160 Ser Ser Leu He Gly Ser Gly Cys Gin He Phe Ala Val Ser Leu He 165 170 175 Val He He Val Ala Met He Glu Asp Leu Tyr Thr Glu Arg Gly Ser 180 185 190 Met Leu Ser Thr Ala He Phe Val Tyr Ala Ala Thr Ser Pro Val Asn 195 200 205 Gly Tyr Phe Gly Gly Ser Leu Tyr Ala Arg Gin Gly Gly Arg Arg Trp 210 215 220 He Lys Gin Met Phe He Gly Ala Phe Leu He Pro Ala Met Val Cys 225 230 235 240 Gly Thr Ala Phe Phe He Asn Phe He Ala He Tyr Tyr His Ala Ser 245 250 255 Arg Ala He Pro Phe Gly Thr Met Val Ala Val Cys Cys He Cys Phe 260 265 270 Phe Val He Leu Pro Leu Asn Leu Val Gly Thr He Leu Gly Arg Asn 275 280 285 Leu Ser Gly Gin Pro Asn Phe Pro Cys Arg Val Asn Ala Val Pro Arg 290 295 300 Pro He Pro Glu Lys Lys Trp Phe Met Glu Pro Ala Val He Val Cys 305 310 315 320 Leu Gly Gly He Leu Pro Phe Gly Ser He Phe He Glu Met Tyr Phe 325 330 335 He Phe Thr Ser Phe Trp Ala Tyr Lys He Tyr Tyr Val Tyr Gly Phe 340 345 350 Met Met Leu Val Leu Val He Leu Cys He Val Thr Val Cys Val Thr 355 360 365 He Val Cys Thr Tyr Phe Leu Leu Asn Ala Glu Asp Tyr Arg Trp Gin 370 375 380 Trp Thr Ser Phe Leu Ser Ala Ala Ser Thr Ala He Tyr Val Tyr Met 385 390 395 400 Tyr Ser Phe Tyr Tyr Tyr Phe Phe Lys Thr Lys Met Tyr Gly Leu Phe 405 410 415 Gin Thr Ser Phe Tyr Phe Gly Tyr Met Ala Val Phe Ser Thr Ala Leu 420 425 430 Gly He Met Cys Gly Ala He 435 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1317 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY, linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO : 2: ATGTACATAG ATGATTTACC AATATGGGGT ATTGTTGGTG AGGCTGATGA AAATGGAGAA 60 GATTACTATC TTTGGACCTA TAAAAAACTT GAAATAGGTT TTAATGGAAA TCGAATTGTT 120 GATGTTAATC TAACTAGTGA AGGAAAGGTG AAACTGGTTC CAAATACTAA AATCCAGATG 180 TCATATTCAG TAAAATGGAA AAAGTCAGAT GTGAAATTTG AAGATCGATT TGACAAATAT 240 CTTGATCCGT CCTTTTTTCA ACATCGGATT CATTGGTTTT CAATTTTCAA CTCCTTCATG 300 ATGGTGATCT TCTTGGTGGG CTTAGTTTCA ATGATTTTAA TGAGAACATT AAGAAAAGAT 360 TATGCTCGGT ACAGTAAAGA GGAAGAAATG GATGATATGG ATAGAGACCT AGGAGATGAA 420 TATGGATGGA AACAGGTGCA TGGAGATGTA TTTAGACCAT CAAGTCACCC ACTGATATTT 480 TCCTCTCTGA TTGGTTCTGG ATGTCAGATA TTTGCTGTGT CTCTCATCGT TATTATTGTT 540 GCAATGATAG AAGATTTATA TACTGAGAGG GGATCAATGC TCAGTACAGC CATATTTGTC 600 TATGCTGCTA CGTCTCCAGT GAATGGTTAT TTTGGAGGAA GTCTGTATGC TAGACAAGGA 660 GGAAGGAGAT GGATAAAGCA GATGTTTATT GGGGCATTCC TTATCCCAGC TATGGTGTGT 720 GGCACTGCCT TCTTCATCAA TTTCATAGCC ATTTATTACC ATGCTTCAAG AGCCATTCCT 780 TTTGGAACAA TGGTGGCCGT TTGTTGCATC TGTTTTTTTG TTATTCTTCC TCTAAATCTT 840 GTTGGTACAA TACTTGGCCG AAATCTGTCA GGTCAGCCCA ACTTTCCTTG TCGTGTCAAT 900 GCTGTGCCTC GTCCTATACC GGAGAAAAAA TGGTTCATGG AGCCTGCGGT TATTGTTTGC 960 CTGGGTGGAA TTTTACCTTT TGGTTCAATC TTTATTGAAA TGTATTTCAT CTTCACGTCT 1020 TTCTGGGCAT ATAAGATCTA TTATGTCTAT GGCTTCATGA TGCTGGTGCT GGTTATCCTG 1080 TGCATTGTGA CTGTCTGTGT GACTATTGTG TGCACATATT TTCTACTAAA TGCAGAAGAT 1140 TACCGGTGGC AATGGACAAG TTTTCTCTCT GCTGCATCAA CTGCAATCTA TGTTTACATG 1200 TATTCCTTTT ACTACTATTT TTTCAAAACA AAGATGTATG GCTTATTTCA AACATCATTT 1260 TACTTTGGAT ATATGGCGGT ATTTAGCACA GCCTTGGGGA TAATGTGTGG AGCGATT 1317 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 965 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: CAGATGTCAT ATTCAGTAAA ATGGAAAAAG TCAGATGTGA AATTTGAAGA TCGATTTGAC 60 AAATATCTTG ATCCGTCCTT TTTTCAACAT CGGATTCATT GGTTTTCAAT TTTCAACTCC 120 TTCATGATGG TGATCTTCTT GGTGGGCTTA GTTTCAATGA TTTTAATGAG AACATTAAGA 180 AAAGATTATG CTCGGTACAG TAAAGAGGAA GAAATGGATG ATATGGATAG AGACCTAGGA 240 GATGAATATG GATGGAAACA GGTGCATGGA GATGTATTTA GACCATCAAG TCACCCACTG 300 ATATTTTCCT CTCTGATTGG TTCTGGATGT CAGATATTTG CTGTGTCTCT CATCGTTATT 360 ATTGTTGCAA TGATAGAAGA TTTATATACT GAGAGGGGAT CAATGCTCAG TACAGCCATA 420 TTTGTCTATG CTGCTACGTC TCCAGTGAAT GGTTATTTTA GAGGAAGTCT GTATGCTAGA 480 CAAGGAGGAA GGAGATGGAT AAAGCAGATG TTTATTGGGG CATTCCTTAT CCCAGCTATG 540 GTGTGTGGCA CTGCCTTCTT CATCAATTTC ATAGCCATTT ATTACCATGC TTCAAGAGCC 600 ATTCCTTTTG GAACAATGGT GGCCGTTTGT TGCATCTGTT TTTTTGTTAT TCTTCCTCTA 660 AATCTTGTTG GTACAATACT TGGCCGAAAT CTGTCAGGTC AGCCCAACTT TCCTTGTCGT 720 GTCAATGCTG TGCCTCGTCC TATACCGGAG AAAAAATGGT TCATGGAGCC TGCGGTTATT 780 GTTTGCCTGG GTGGAATTTT ACCTTTTGGT TCAATCTTTA TTGAAATGTA TTTCATCTTC 840 ACGTCTTTCT GGGCATATAA GATCTATTAT GTCTATGGCT TCATGATGCT GGTGCTGGTT 900 ATCCTGTGCA TTGTGACTGT CTGTGTGACT ATTGTGTGCA CATATTTTCT ACTAAATGCA 960 GAAGA 965 (2) INFORMATION FOR SEQ ID NO : 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 285 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: TCAGTAAAAT GGAAAAAGTC AGATGTGAAA TTTGAAGATC GATTTGACAA ATATCTTGAT 60 CCGTCCTTTT TTCAACATCG GATTCATTGG TTTTCAATTT TCAACTCCTT CATGATGGTG 120 ATCTTCTTGG TGGGCTTAGT TTCAATGATT TTAATGAGAA CATTAAGAAA AGATTATGCT 180 CGGTACAGTA AAGAGGAAGA AATGGATGAT ATGGATAGAG ACCTAGGAGA TGAATATGGA 240 TGGAAACAGG TGCATGGAGA TGTATTTAGA CCATCAAGTC ACCCA 285 (2) INFORMATION FOR SEQ ID NO: 5- (l) SEQUENCE CHARACTERISTICS: (A) LENGTH. 17 ammo acids (B) TYPE: ammo acid (C) STRANDEDNESS. single (D) TOPOLOGY, linear ( ii ) MOLECULE TYPE : peptide ( xi ) SEQUENCE DESCRIPTION : SEQ ID NO : 5 - Asp Pro Ser Phe Phe Gin His Arg He His Trp Phe Ser He Phe Asn 1 5 10 15 Ser (2) INFORMATION FOR SEQ ID NO. 6: (l) SEQUENCE CHARACTERISTICS. (A) LENGTH. 17 ammo acids (B) TYPE- amino acid (C) STRANDEDNESS. single (D) TOPOLOGY: linear ( ii ) MOLECULE TYPE : peptide ( xi ) SEQUENCE DESCRIPTION : SEQ ID NO - 6 . Asp Pro Xaa Phe Phe Gin His Arg He His Val Phe Ser He Phe Asn 1 5 10 15 His (2) INFORMATION FOR SEQ ID NO: 7: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE, nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY, linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "AMORCE" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7 TCAGTAAAAT GGAAAAAGTC 0 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "AMORCE" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: TGGGTGACTT GATGGTCTAA 0 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "AMORCE" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: GCTGTGTCTC TCATCGTTA 19 (2) INFORMATION FOR SEQ ID NO : 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "AMORCE" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: CCATCCATAT TCATCTCCTA 20 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "AMORCE" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: CGGTATAGGA CGAGGCACAG C 21 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: other nucleic acid (A) DESCRIPTION: /desc = "AMORCE" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: ACTGAATATG ACATCTGG 18 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1800 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: ..1730 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: CC GCC GCG CTG TGG CTG CTG CTG CTG CTG CTG CCC CGG A.CC CGG GCG 47 Ala Ala Leu Trp Leu Leu Leu Leu Leu Leu Pro Arg Thr Arg Ala 1 5 10 15 GAC GAG CAC GAA CAC ACG TAT CAA GAT AAA GAG GAA GTT GTC TTA TGG 95 Asp Glu His Glu His Thr Tyr Gin Asp Lys Glu Glu Val Val Leu Trp 20 25 30 ATG AAT ACT GTT GGG CCC TAC CAT AAT CGT CAA GAA ACA TAT AAG TAC 143 Met Asn Thr Val Gly Pro Tyr His Asn Arg Gin Glu Thr Tyr Lys Tyr 35 40 45 TTT TCA CTT CCA TTC TGT GTG GGG TCA AAA AAA AGT ATC AGT CAT TAC 191 Phe Ser Leu Pro Phe Cys Val Gly Ser Lys Lys Ser He Ser His Tyr 50 55 60 CAT GAA ACT CTG GGA GAA GCA CTT CAA GGG GTT GAA TTG GAA TTT AGT 239 His Glu Thr Leu Gly Glu Ala Leu Gin Gly Val Glu Leu Glu Phe Ser 65 70 75 GGT CTG GAT ATT AAA TTT AAA GAT GAT GTG ATG CCA GCC ACT TAC TGT 287 Gly Leu Asp He Lys Phe Lys Asp Asp Val Met Pro Ala Thr Tyr Cys 80 85 90 95 GAA ATT GAT TTA GAT AAA GAA AAG AGA GAT GCA TTT GTA TAT GCC ATA 335 Glu He Asp Leu Asp Lys Glu Lys Arg Asp Ala Phe Val Tyr Ala He 100 105 110 AAA AAT CAT TAC TGG TAC CAG ATG TAC ATA GAT GAT TTA CCA ATA TGG 383 Lys Asn His Tyr Trp Tyr Gin Met Tyr He Asp Asp Leu Pro He Trp 115 120 125 GGT ATT GTT GGT GAG GCT GAT GAA AAT GGA GAA GAT TAC TAT CTT TGG 431 Gly He Val Gly Glu Ala Asp Glu Asn Gly Glu Asp Tyr Tyr Leu Trp 130 135 140 ACC TAT AAA AAA CTT GAA ATA GGT TTT AAT GGA AAT CGA ATT GTT GAT 479 Thr Tyr Lys Lys Leu Glu He Gly Phe Asn Gly Asn Arg He Val Asp 145 150 155 GTT AAT CTA ACT AGT GAA GGA AAG GTG AAA CTG GTT CCA AAT ACT AAA 527 Val Asn Leu Thr Ser Glu Gly Lys Val Lys Leu Val Pro Asn Thr Lys 160 165 170 175 ATC CAG ATG TCA TAT TCA GTA AAA TGG AAA AAG TCA GAT GTG AAA TTT 575 He Gin Met Ser Tyr Ser Val Lys Trp Lys Lys Ser Asp Val Lys Phe 180 185 190 GAA GAT CGA TTT GAC AAA TAT CTT GAT CCG TCC TTT TTT CAA CAT CGG 623 Glu Asp Arg Phe Asp Lys Tyr Leu Asp Pro Ser Phe Phe Gin His Arg 195 200 205 ATT CAT TGG TTT TCA ATT TTC AAC TCC TTC ATG ATG GTG ATC TTC TTG 671 He His Trp Phe Ser He Phe Asn Ser Phe Met Met Val He Phe Leu 210 215 220 GTG GGC TTA GTT TCA ATG ATT TTA ATG AGA ACA TTA AGA AAA GAT TAT 719 Val Gly Leu Val Ser Met He Leu Met Arg Thr Leu Arg Lys Asp Tyr 225 230 235 GCT CGG TAC AGT AAA GAG GAA GAA ATG GAT GAT ATG GAT AGA GAC CTA 767 Ala Arg Tyr Ser Lys Glu Glu Glu Met Asp Asp Met Asp Arg Asp Leu 240 245 ~ 250 " 255 GGA GAT GAA TAT CCA 815 Gly Asp Glu Tyr Pro TCA AGT CAC CCA CTG ATA TTT TCC TCT CTG ATT GGT TCT GGA TGT CAG 863 Ser Ser His Pro Leu He Phe Ser Ser Leu He Gly Ser Gly Cys Gin 275 280 285 ATA TTT GCT GTG TCT CTC ATC GTT ATT ATT GTT GCA ATG ATA GAA GAT 911 He Phe Ala Val Ser Leu He Val He He Val Ala Met He Glu Asp 290 295 300 TTA TAT ACT GAG AGG GGA TCA ATG CTC AGT ACA GCC ATA TTT GTC TAT 959 Leu Tvr Thr Glu Arg Gly Ser Met Leu Ser Thr Ala He Phe Val Tyr 305 310 315 GCT GCT ACG TCT CCA GTG AAT GGT TAT TTT GGA GGA AGT CTG TAT GCT 1007 Ala Ala Thr Ser Pro Val Asn Gly Tyr Phe Gly Gly Ser Leu Tyr Ala 320 325 330 335 AGA CAA GGA GGA AGG AGA TGG ATA AAG CAG ATG TTT ATT GGG GCA TTC 1055 Arg Gin Gly Gly Arg Arg Trp He Lys Gin Met Phe He Gly Ala Phe 340 345 350 CTT ATC CCA. GCT ATG GTG TGT GGC ACT GCC TTC TTC ATC AAT TTC ATA 1103 Leu He Pro Ala Met Val Cys Gly Thr Ala Phe Phe He Asn Phe He 355 360 365 GCC ATT TAT TAC CAT GCT TCA AGA GCC ATT CCT TTT GGA ACA ATG GTG 1151 Ala He Tvr Tyr His Ala Ser Arg Ala He Pro Phe Gly Thr Met Val 370 375 380 GCC GTT TGT TGC ATC TGT TTT TTT GTT ATT CTT CCT CTA AAT CTT GTT 1199 Ala Val Cys Cys He Cys Phe Phe Val He Leu Pro Leu Asn Leu Val 385 390 395 GGT ACA ATA CTT GGC CGA AAT CTG TCA GGT CAG CCC AAC TTT CCT TGT 1247 Gly Thr He Leu Gly Arg Asn Leu Ser Gly Gin Pro Asn Phe Pro Cys 400 405 410 415 CGT GTC AAT GCT GTG CCT CGT CCT ATA CCG GAG AAA AAA TGG TTC ATG 1295 Arg Val Asn Ala Val Pro Arg Pro He Pro Glu Lys Lys Trp Phe Met 420 425 430 GAG CCT GCG GTT ATT GTT TGC CTG GGT GGA ATT TTA CCT TTT GGT TCA 1343 Glu Pro Ala Val He Val Cys Leu Gly Gly He Leu Pro Phe Gly Ser 435 440 445 ATC TTT ATT GAA ATG TAT TTC ATC TTC ACG TCT TTC TGG GCA TAT AAG 1391 He Phe He Glu Met Tyr Phe He Phe Thr Ser Phe Trp Ala Tyr Lys 450 455 460 ATC TAT TAT GTC TAT GGC TTC ATG ATG CTG GTG CTG GTT ATC CTG TGC 1439 He Tyr Tyr Val Tyr Gly Phe Met Met Leu Val Leu Val He Leu Cys 465 470 475 ATT GTG ACT GTC TGT GTG ACT ATT GTG TGC ACA TAT TTT CTA CTA AAT 1487 He Val Thr Val Cys Val Thr He Val Cys Thr Tyr Phe Leu Leu Asn 480 485 490 495 GCA GAA GAT TAC CGG TGG CAA TGG ACA AGT TTT CTC TCT GCT GCA TCA 1535 Ala Glu Asp Tyr Arg Trp Gin Trp Thr Ser Phe Leu Ser Ala Ala Ser 500 505 510 ACT GCA ATC TAT GTT TAC ATG TAT TCC TTT TAC TAC TAT TTT TTC AAA 1583 Thr Ala He Tyr Val Tyr Met Tyr Ser Phe Tyr Tyr Tyr Phe Phe Lys 515 520 525 ACA AAG ATG TAT GGC TTA TTT CAA ACA TCA TTT TAC TTT GGA TAT ATG 1631 Thr Lys Met Tyr Gly Leu Phe Gin Thr Ser Phe Tyr Phe Gly Tyr Met 530 535 540 GCG GTA TTT AGC ACA GCC TTG GGG ATA ATG TGT GGA GCG ATT GGT TAC 1679 Ala Val Phe Ser Thr Ala Leu Gly He Met Cys Gly Ala He Gly Tyr 545 550 555 ATG GGA ACA AGT GCC TTT GTC CGA AAA ATC TAT ACT AAT GTG AAA ATT 1727 Met Gly Thr Ser Ala Phe Val Arg Lys He Tyr Thr Asn Val Lys He 560 565 570 575 GAC TAGAGACCCA AGAAAACCTG GAACTTTGGA TCAATTTCTT TTTCATAGGG 1780 Asp GTGGAACTTG CACAGCAAAA 1800 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 576 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: Ala Ala Leu Trp Leu Leu Leu Leu Leu Leu Pro Arg Thr Arg Ala Asp 1 5 10 15 Glu His Glu His Thr Tyr Gin Asp Lys Glu Glu Val Val Leu Trp Met 20 25 30 Asn Thr Val Gly Pro Tyr His Asn Arg Gin Glu Thr Tyr Lys Tyr Phe 35 40 45 Ser Leu Pro Phe Cys Val Gly Ser Lys Lys Ser He Ser His Tyr His 50 55 60 Glu Thr Leu Gly Glu Ala Leu Gin Gly Val Glu Leu Glu Phe Ser Gly 65 70 75 80 Leu Asp He Lys Phe Lys Asp Asp Val Met Pro Ala Thr Tyr Cys Glu 85 90 95 He ASD Leu Asp Lys Glu Lys Arg Asp Ala Phe Val Tyr Ala He Lys 100 105 110 Asn His Tyr Trp Tyr Gin Met Tyr He Asp Asp Leu Pro He Trp Gly 115 120 125 He Val Gly Glu Ala Asp Glu Asn Gly Glu Asp Tyr Tyr Leu Trp Thr 130 135 140 Tyr Lys Lys Leu Glu He Gly Phe Asn Gly Asn Arg He Val Asp Val 145 150 155 160 Asn Leu Thr Ser Glu Gly Lys Val Lys Leu Val Pro Asn Thr Lys He 165 170 175 Gin Met Ser Tyr Ser Val Lys Trp Lys Lys Ser Asp Val Lys Phe Glu 180 185 190 Asp Arg Phe Asp Lys Tyr Leu Asp Pro Ser Phe Phe Gin His Arg He 195 200 205 His Trp Phe Ser He Phe Asn Ser Phe Met Met Val He Phe Leu Val 210 215 220 Gly Leu Val Ser Met He Leu Met Arg Thr Leu Arg Lys Asp Tyr Ala 225 230 235 240 Arg Tyr Ser Lys Glu Glu Glu Met Asp Asp Met ASD Arg Asp Leu Gly 245 250 " 255 Asp Glu Tyr Gly Trp Lys Gin Val His Gly Asp Val Phe Arg Pro Ser 260 265 270 Ser His Pro Leu He Phe Ser Ser Leu He Gly Ser Gly Cys Gin He 275 280 285 Phe Ala Val Ser Leu He Val He He Val Ala Met He Glu Asp Leu 290 295 300 Tyr Thr Glu Arg Gly Ser Met Leu Ser Thr Ala He Phe Val Tyr Ala 305 310 315 320 Ala Thr Ser Pro Val Asn Gly Tyr Phe Gly Gly Ser Leu Tyr Ala Arg 325 330 335 Gin Gly Gly Arg Arg Trp He Lys Gin Met Phe He Gly Ala Phe Leu 340 345 350 He Pro Ala Met Val Cys Gly Thr Ala Phe Phe He Asn Phe He Ala 355 360 365 He Tyr Tyr His Ala Ser Arg Ala He Pro Phe Gly Thr Met Val Ala 370 375 330 Val Cys Cys He Cys Phe Phe Val He Leu Pro Leu Asn Leu Val Gly 385 390 395 400 Thr He Leu Gly Arg Asn Leu Ser Gly Gin Pro Asn Phe Pro Cys Arg 405 410 415 Val Asn Ala Val Pro Arg Pro He Pro Glu Lys Lys Trp Phe Met Glu 420 425 430 Pro Ala Val He Val Cys Leu Gly Gly He Leu Pro Phe Gly Ser He 435 440 445 Phe He Glu Met Tyr Phe He Phe Thr Ser Phe Trp Ala Tyr Lys He 450 455 460 Tyr Tyr Val Tyr Gly Phe Met Met Leu Val Leu Val He Leu Cys He 465 470 475 480 Val Thr Val Cys Val Thr He Val Cys Thr Tyr Phe Leu Leu Asn Ala 485 490 495 Glu Asp Tyr Arg Trp Gin Trp Thr Ser Phe Leu Ser Ala Ala Ser Thr 500 505 510 Ala He Tyr Val Tyr Met Tyr Ser Phe Tyr Tyr Tyr Phe Phe Lys Thr 515 520 525 Lys Met Tyr Gly Leu Phe Gin Thr Ser Phe Tyr Phe Gly Tyr Met Ala 530 535 540 Val Phe Ser Thr Ala Leu Gly He Met Cys Gly Ala He Gly Tyr Met 545 550 555 560 Gly Thr Ser Ala Phe Val Arg Lys He Tyr Thr Asn Val Lys He ASD 565 570 575

Claims: CLAIMS 1°) Substantially pure mammal polypeptide. characterized in that it contains sites such that when said sites are exposed at the surface of a ceil, they are able of binding iodocyanopindolol (ICYP) under blockade of α, β l , β2, β3-AR, serotonine 5- HT IA and serotonine 5-HTIB receptors, said binding being saturable, reversible, able to be displaced by a β-adrenergic receptor agonist SM- 1 1044 with stereoselectivity but not by isoproterenol, norepinephrine, epinephrine, serotonine, dopamine or BRL-37344, and not being blocked by propranolol, said polypeptide (1) having an apparent molecular weight of about 30-40 kDa when labeled with I-iodocyanopindolol after photoaffinity labeling and separation by electrophoresis and an apparent molecular weight of about 60-80 kDa in Western blot, and (2) generating a fragment having the following formula DPXιFFQHRIHX FSIFNX 3 by acidic cleavage, wherein, X, represents S (SEQ ID N°5) or X (SEQ ED N°6), X 2 represents V (SEQ ID N°6) or W (SEQ ID N°5) and X 3 represents S (SEQ ID N°5) or H (SEQ ID N°6), said polypeptide being present at least on muscles and eosinophils membranes and being a non-adrenergic receptor. 2°) The polypeptide according to claim 1, characterized in that it contains at least SEQ ID NO: l. 3°) The polypeptide according to claim 1, characterized in that it consists of SEQ ID NO: 13. 4°) An isolated and purified nucleic acid sequence, characterized in that it encodes a mammalian receptor as claimed in claim 1. 5°) The isolated and purified nucleic acid sequence of claim 4, characterized in that it includes at least SEQ ID NO:2. 6°) The isolated and purified nucleic acid sequence of claim 4, characterized in that it consists of SEQ ID NO: 14. 7°) The purified nucleic acid sequence according to claim 4 or claim 5, characterized in that it hybridizes with SEQ ID NO:3 or SEQ ID NO:4. 8°) cDNA clones, characterized in that they comprise a sequence coding for the instant non-adrenergic receptor according to claim 1. 9°) Synthetic or non-synthetic nucleotide probes, characterized in that they hybridize with a nucleic acid according to claims 4 to 8 or with their complementary sequences or their corresponding RNA, these probes being such that they do not hybridize with the genes or the messenger RNA coding for β-adrenergic receptors. 10°) Probes according to claim 9, characterized in that they are selected from the group consisting of SEQ ID NO:3, SEQ ID NO: 4 and SEQ ID NO: 7 to SEQ ID NO: 12, optionally labeled using a label such as a radioactive isotope, a suitable enzyme or a fluorochrome. 11°) Primers for amplifying a nucleic acid sequence according to claims 4 to 8, characterized in that they are selected from the group consisting of SEQ ID NO:7 to SEQ ID NO: 12. 12°) A recombinant plasmid in particular for cloning and/or expression, containing a nucleic acid sequence according to claims 4 to 8 at one of its cloning sites non essential for its replication. 13°) The recombinant plasmid according to claim 12, characterized in that it further comprises an origin of replication for replication in a host cell, at least one gene whose expression permits selection of said host cell transformed with said plasmid, and a regulatory sequence, including a promoter permitting expression of a polypeptide having a non-adrenergic activity as defined hereabove, in said host cell. 14°) The recombinant plasmid according to claim 12, characterized in that said plasmid is pcDNA3 into which is inserted, in a multisite linker. SEQ ID NO:2, wherein said plasmid is deposited with the Collection Nationale de Cultures de Microorganismes [National Collection of Microorganism Cultures] (CNCM held by the PASTEUR INSTITUTE, dated December 10, 1996, under No. 1-1795. 15°) A host cell transformed by a recombinant plasmid according to claims 12 to 14, characterized in that it comprises the elements of regulation making possible the expression of the nucleotide sequence coding for the instant polypeptide in this host. 16°) The host cell according to claim 15, characterized in that it consists, in particular, in mammalian cell lines. 17°) Antibodies directed specifically against the instant polypeptide according to claim 1 , these antibodies being such that they recognize neither known α or β-adrenergic, nor serotonine, nor dopamine receptors. 18°) A method for assaying a substance for agonist or antagonist activity towards a polypeptide according to claim 1, which method comprises: - placing the substance in contact with tissue membrane proteins or a transformed host cell expressing a polypeptide according to claim 1 under conditions which permit binding between said polypeptide binding sites and an agonist or an antagonist thereto and - measuring an appropriate transduction signal. 19°) A process for studying the binding affinity of a compound for a polypeptide according to claim 1, which process comprises: - transforming a host cell by an expression vector comprising a nucleotide sequence coding for the instant receptor, - culturing said transformed host cell under conditions which permit the expression or said receptor encoded by said nucleotide sequence and the transfer of the expressed receptor polypeptide to the membrane of the said transformed host cell so that transmembrane sequences of said receptor polypeptide are embedded in the cell membranes of the transformed host cell; - placing said transformed host cell in contact with said compound and - measuring the quantity of said compound bond to said receptor polypeptide. 20°) A process for studying the binding affinity of a compound for a polypeptide according to claim 1, which process comprises: - extracting membrane proteins corresponding to the instant receptor polypeptide from appropriate tissues or cells such as muscles, - placing said membrane proteins in contact with said compound and - measuring the quantity of said compound bond to said receptor polypeptide. 21°) Method of preparation of a polypeptide according to claim 1, which method comprises: - preparing membrane proteins from a tissue containing the instant polypeptide, such as rat colon or human skeletal muscle, - labeling said membrane proteins with [ I]-ICYP-diazirine or another appropriate marker under blockade of α, βl, β2, β3-AR and serotonine receptors, - separating said labeled proteins by preparative SDS-PAGE electro- phoresis and - extracting the radioactive band.

Inventors: LENZEN GERLINDE, MOROOKA SHIGEAKI, STROSBERG ARTHUR DONNY, SUGASAWA TOSHINARI, LENZEN, GERLINDE, MOROOKA, SHIGEAKI, STROSBERG, ARTHUR, DONNY, SUGASAWA, TOSHINARI
Applicants: LENZEN GERLINDE, MOROOKA SHIGEAKI, STROSBERG ARTHUR DONNY, SUGASAWA TOSHINARI, VETIGEN, LENZEN, GERLINDE, MOROOKA, SHIGEAKI, STROSBERG, ARTHUR, DONNY, SUGASAWA, TOSHINARI
Application year: 1997
Main classification: C12N15
IPC codes: C07K14, C12N15